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ABSTRACT

Hemoglobinopathies are some of the most common monogenic disorders in the
world, affecting millions of people and representing a growing burden on health systems
worldwide. Although the pathophysiology of sickle cell anemia and -thalassemia, two
of the most common hemoglobinopathies, have been the focus of much research over
the last century, patients affected by these diseases still lack a widely applicable and
easily available cure. Sickle cell anemia and -thalassemia are caused by defects in the
structure and production of the -globin chains that, along with the -globin chains
make up the heterotetrameric hemoglobin molecule. Studies geared towards reexpression of the silenced fetal -globin gene in adult erythroid cells as a therapeutic
strategy to alleviate the symptoms of -globin deficiencies have met with some success
for the treatment of sickle cell anemia but not for -thalassemia. A better understanding
of normal -globin gene regulation will undoubtedly advance the development of more
effective therapeutic strategies. Because many of the potential targets that may be
modulated to achieve -globin re-expression also have functions in erythroid cells other
than regulating the -globin gene, it is imperative to understand their role in all aspects
of erythropoiesis before they are used for therapy.
The current study focuses on the role of two Krüppel-like transcription factors,
KLF1 and KLF2, which have known roles in the processes of primitive and definitive
erythropoiesis as well as globin gene regulation. The regulation of primitive
erythropoiesis by KLF1 and KLF2 is studied using the mouse as a model system

xvi

because it is not possible to study primitive erythropoiesis in humans. Previous studies
have shown that KLF1 and KLF2 are essential for and have overlapping roles in
primitive erythropoiesis. Simultaneous ablation of KLF1 and KLF2 results in a severely
anemic embryonic phenotype that is not evident in KLF1 or KLF2 single knockout
embryos. In this study, we show that this anemia is caused by a paucity of blood cells,
and exacerbated by diminished -like globin gene expression. The anemia phenotype is
dose-dependent, and interestingly, can be ameliorated by a single copy of the KLF2, but
not the KLF1 gene. The roles of KLF1 and KLF2 in maintaining both normal peripheral
blood cell numbers and globin mRNA amounts are erythroid cell-specific. It was
discovered that KLF2 has an essential function in erythroid precursor maintenance.
KLF1 can partially compensate for KLF2 in this role, but is uniquely crucial for erythroid
precursor proliferation, through its regulation of G1- to S-phase cell cycle transition. A
more drastic impairment of primitive erythroid colony formation from embryonic
progenitor cells occurs with simultaneous deficiency of KLF1 and KLF2, than with loss
of a single factor.
The regulation of human -like globin gene expression is studied using a recently
developed in vitro system for the production of erythroid cells from umbilical cord blood
hematopoietic precursor cells, representing a more “fetal” model of globin gene
expression. Previous studies have shown that KLF1 binds to the promoters of the - and
-globin genes, while KLF2 binds to the promoter of the -globin gene in cord bloodderived erythroid cells. Studies using transgenic mice carrying the entire human globin locus had indicated that KLF1 and KLF2 positively regulate -globin expression in
mouse embryonic erythroid cells. We demonstrate in this study that KLF1 appears to
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have dual roles in the regulation of -globin expression in human cord blood-derived
definitive erythroid cells. Partial depletion of KLF1 causes elevated -globin expression,
while nearly complete depletion of KLF1 results in a down-regulation of -globin
expression. Of particular interest was the observation that KLF2 positively regulates globin expression in cord blood-derived erythroid cells. Surprisingly, KLF2 also
positively regulates -globin expression in these cells. If regulation of -globin by KLF2
proves to be a direct effect, KLF2 will join a very small group of factors known to directly
activate -globin expression.

Chapter 1: Introduction

The blood is an essential body fluid, primarily composed of plasma, red blood
cells, white blood cells and platelets. Its principal function is the delivery of oxygen and
nutrients to, and the retrieval of waste products from all cells of the body. Blood cells
account for 45% of the composition of blood and plasma makes up the remaining 55%.
All of the different types of blood cells are derived from a common precursor cell by a
process called hematopoiesis (Fig. 1.1). This common precursor is known as the
hematopoietic stem cell (HSC). HSCs are capable of long term self-renewal as well as
producing all the types of differentiated cells found in blood: red blood cells, white blood
cells and platelets. As depicted in Figure 1.1, there are a number of intermediate
progenitor and precursor cells between the HSC and the various blood cells. While the
exact identity/molecular signature of the HSC is still unknown, the various
intermediaries between the HSC and mature cells of each lineage can be identified
either by morphology or retrospectively by the types of colonies they produce in colony
formation assays. The focus of this study is the process of erythropoiesis or the
production of red blood cells, also known as erythrocytes. Erythrocytes are the most
abundant cell type present in blood. They get their characteristic red color from
hemoglobin, the respiratory substrate.
1.1 Erythropoiesis: When, Where and How?
Erythropoiesis is a complex, multistep developmental process that, in mammals,
consists of two discernable phases or “waves” of red blood cell genesis (Palis 2008).
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Figure 1.1: Hematopoiesis is the process of formation of all the different types of
blood cells from the hematopoietic stem cell (HSC).
LT-HSC – Long-term repopulating HSC, ST-HSC – short-term repopulating HSC, MPP multipotent progenitor, CMP - common myeloid progenitor, CLP - common lymphoid
progenitor, MEP - megakaryocyte/erythroid progenitor, GMP - granulocyte–macrophage
progenitor. Figure adapted from Larsson J, et al. Oncogene (2005) 24, 5676–5692
(Larsson and Karlsson 2005).
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These waves are termed primitive and definitive erythropoiesis, and result in the
production of primitive and definitive erythroid cells, respectively.
1.1.1 Primitive erythropoiesis
Primitive erythropoiesis is a transient wave of erythropoiesis that occurs during
early embryonic life in the yolk sac, in regions called blood islands, and gives rise to the
first mammalian erythroid cells (Ferkowicz and Yoder 2005; Haar and Ackerman 1971).
These erythroid cells were termed “primitive” since they morphologically resemble the
nucleated erythroid cells of non-mammalian vertebrates (McGrath and Palis 2008).
Recent studies have shown that the primitive erythroid lineage is more similar to the
definitive erythroid lineage than was previously suspected, and mature primitive
erythroid cells enucleate in circulation (Baron 2013). Primitive erythroid cells arise as
large, nucleated cells from progenitors known as primitive erythroid colony-forming cells
(EryP-CFC) (McGrath and Palis 2008). In the mouse, EryP-CFC are detected in the yolk
sac at embryonic day 7.25 (E7.25), undergo a brief expansion, and fall off/cease to exist
by E9 (Palis et al. 1999). Primitive erythroid cells arise around E7.5 and begin to
circulate at E8.25 (Palis 2008). They mature in circulation as a synchronous cohort,
from

proerythroblasts

to

basophilic,

polychromatophilic

and

orthochromatic

erythroblasts, and eventually undergo enucleation between E12.5 and E16.5 (Fig. 1.2)
(Kingsley et al. 2004). In humans, blood islands are observed at 18-20 days of gestation
and primitive erythroblasts are the sole erythroid cells in circulation until 6 weeks of
gestation (Luckett 1978; Palis 2014).

3

Figure 1.2: Primitive vs Definitive erythropoiesis. Erythropoiesis in mammals is
defined by two successive waves of red blood cell genesis known as primitive and
definitive erythropoiesis.
HSC – hematopoietic stem cell, BFU-E – burst-forming unit erythroid, CFU-E – colonyforming unit erythroid, EryP-CFC – primitive erythroid colony forming cells, ProE –
proerythroblast, BasoE – basophilic erythroblast, PolyE – polychromatophilic
erythroblast, OrthoE – orthochromatic erythroblast, Retic – reticulocyte, RBC – red
blood cell, MAC – macrophage, E – embryonic day.
Figure adapted from Palis J. Front Physiol. 2014 (Palis 2014).
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1.1.2 Definitive erythropoiesis
The

second

wave

of

erythropoiesis

in

mammals

is

called

definitive

erythropoiesis. The liver is the site of definitive erythropoiesis during fetal life. After birth,
the site of erythropoiesis switches to the bone marrow. Both of these sites are
repositories for hematopoietic stem cells which give rise to definitive erythroid progenitor
cells (Palis 2014). There are two types of definitive erythroid progenitor cells, the burstforming unit erythroid or BFU-E and the colony forming unit erythroid or CFU-E, defined
on the basis of the types of colonies they produce in semi-solid media. These
progenitors generate nucleated definitive erythroid precursor cells that progressively
mature from proerythroblasts to basophilic, polychromatophilic and orthochromatic
erythroblasts within either the fetal liver or bone marrow, until they finally undergo
enucleation to form reticulocytes which are released into circulation (Fig. 1.2) (Palis
2014). Reticulocytes undergo organelle clearance and cytoskeletal changes to become
mature red blood cells (Johnstone 1992). Definitive erythroid cells are seen in mouse
fetal circulation starting from E11.5 (McGrath et al. 2011).
1.1.3 Identification of various erythroid progenitor and precursor cells
The three types of erythroid progenitor cells, the primitive EryP-CFC, and the
definitive BFU-E and CFU-E, can be identified retrospectively by the types of colonies
they produce in semi-solid culture media supplemented with cytokines necessary for
erythroid differentiation (Fig. 1.3A) (Palis et al. 1999). Proerythroblasts, basophilic
erythroblasts, polychromatophilic erythroblasts, orthochromatic erythroblasts and
mature primitive and definitive erythrocytes can be identified by their morphological
characteristics after staining with Wright-Giemsa (Fig. 1.3B).
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A

EryP-CFC

B

Proerythroblast

Basophilic
erythroblast

Polychromatic Orthochromatic Reticulocyte
erythroblast
erythroblast

Erythrocyte

CD71

C

Ter119

Figure 1.3: Identification of cells of the erythroid lineage. (A) There are three types
of erythroid progenitor cells – primitive erythroid colony forming cells (EryP-CFC), burstforming unit erythroid (BFU-E) and colony-forming unit erythroid (CFU-E) that are
identified retrospectively by the morphology of the colonies they produce in semi-solid
erythroid differentiation media. (B) Hierarchy of erythroid precursor cells found between
erythroid progenitors and mature erythrocytes. (C) Flow cytometry plot showing the
distribution of two cell surface markers CD71 (transferrin receptor) and Ter119 on E13.5
fetal liver erythroid cells. At E13.5 fetal livers contain all the different types of erythroid
precursor cells that can be identified by the relative amount of CD71 and Ter119
expressed on their surface by this method. The five gates R1 to R5 are defined as
follows: R1 (CD71LO Ter119NEG) - early erythroid progenitors, R2 (CD71HI Ter119LO) erythroid progenitors, R3 (CD71HI Ter119HI) - proerythroblasts and basophilic
erythroblasts, R4 (CD71MID Ter119HI) - polychromatic erythroblasts and orthochromatic
erythroblasts, and R5 (CD71LO Ter119HI) - reticulocytes. Figure adapted from (A) Palis
J, et al. Development 1999 (Palis et al. 1999) (C) Pilon AM, et al. Mol Cell Biol. 2008
(Pilon
et
al.
2008)
and
(B)
http://medcell.med.yale.edu/histology/blood_bone_marrow_lab/erythropoiesis.php
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A commonly used flow-cytometric method to determine the relative numbers of
erythroblasts of each of these denominations in a mixed population relies on the
changing expression of two surface markers on maturing erythroid cells (Zhang et al.
2003). For mouse cells the markers used are CD71 (transferrin receptor) and Ter119.
For human cells the markers used are CD71 (transferrin receptor) and Glycophorin A
(GPA or CD235a). Ter119 expression in mouse erythroblasts mirrors Glycophorin A
expression in human erythroblasts. Five compartments, designated R1-R5, are defined
based on the level of expression of each marker, with R1 consisting of the least mature
erythroblasts and R5 consisting of the most mature (Fig. 1.3C). R1 (CD71LO Ter119NEG)
comprises early erythroid progenitors, R2 (CD71HI Ter119LO) contains erythroid
progenitors, R3 (CD71HI Ter119HI) is made up of proerythroblasts and basophilic
erythroblasts, R4 (CD71MID Ter119HI) consists of polychromatic erythroblasts and
orthochromatic erythroblasts, and R5 (CD71LO Ter119HI) consists of reticulocytes (Pilon
et al. 2008).

1.2 Hemoglobin and hemoglobin switching
The most abundant constituent of erythrocytes is hemoglobin, the protein
responsible for the high oxygen-carrying capacity of blood. Hemoglobin is a tetrameric
molecule, composed of two -like globin chains and two β-like globin chains, each of
which co-ordinate an iron-containing heme group (Fig. 1.4). Each iron ion can bind one
molecule of oxygen. The -globin locus, situated on human chromosome 16 and mouse
chromosome 11, consists of three -like globin genes, - (zeta), 2- and 1-globin
(Figs. 1.5 and 1.6).
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Figure 1.4: The hemoglobin molecule. Hemoglobin is a tetrameric metallo-protein
composed of two -like globin chains and two β-like globin chains, each of which coordinates
an
iron-containing
heme
group.
Adapted
from
http://www.as.miami.edu/chemistry/2086/chap19/newchapter%2019-part1.htm
The β-globin locus differs slightly between humans and mice. The human βglobin locus, situated on chromosome 11, consists of the embryonic ε-globin gene, the
fetal -globin gene, and the adult - and β-globin genes. The mouse β-globin locus,
situated on chromosome 7, consists of the embryonic εy- and βh1-globin genes and the
adult βmaj- and βmin-globin genes. The mouse β-globin locus does not have a fetal
globin gene equivalent of the human -globin gene.
The -like and β-like globin genes are developmentally regulated and expressed
in the order in which they are arranged on the chromosome. As a result hemoglobin
molecules expressed at different stages during development are composed of different
-like and β-like chains. This phenomenon of progressively changing globin gene
expression is known as hemoglobin switching (Weatherall 2001). In humans, these
“switches” in the type of hemoglobin expressed are concurrent with changes in the site
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of erythropoiesis. In the yolk sac, - and ε-globin are the respective - and β-like globin
genes initially expressed in primitive erythroid cells (2ε2 or hemoglobin Gower I).
Between 5 and 7 weeks of gestation, primitive erythroid cells switch to expression of
hemoglobin Gower II (2ε2). The next switch in hemoglobin expression is observed in
the fetal liver. Fetal liver definitive erythroid cells express HbF, composed of 2 -globin
chains and 2 -globin chains (22). The final switch in hemoglobin expression is
observed shortly after birth, as the site of erythropoiesis moves to the bone marrow.
Bone marrow-derived adult definitive erythroid cells predominantly express HbA (2β2,
>95%), along with very low levels of HbA2 (22, ~2%) and HbF (<2%). In mice,
primitive erythroid cells initially express -, - and βh1-globin. By E12.5 -globin is
replaced by -globin as the -like globin expressed for the remainder of development
as well as during adult life (Palis et al. 2010). Mouse primitive erythroid cells at E10.5
express predominantly embryonic εy- and βh1-globins, and very low levels of βmaj- and
βmin-globins. A switch in β-like globin gene expression is observed from the embryonic
genes to the adult βmaj and βmin genes in mouse fetal liver erythroid cells between
E11.5 and E12.5, and these genes continue to be expressed for the remainder of fetal
and adult life.
The - and β-like globin mRNA constitute about 90% of total mRNA in erythroid
cells, achieved partly through extremely high levels of globin gene transcription. It was
discovered that while proximal promoter sequences were sufficient to endow tissue- and
development-specific expression of the globin genes, distal sequences were
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Figure 1.5: The human - and -globin loci and a depiction of the process of
hemoglobin switching in humans. Adapted from (1) Stamatoyannopoulos G. Exp
Hematol. 2005 and (2) Weatherall DJ. Nat Rev Genet. 2001.
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B

A

Figure 1.6: The mouse - and -globin loci. (A) The mouse -globin locus consists of
four -like globin genes: εy, βh1, βmaj and βmin, and an upstream locus control region
(LCR). The graph below the locus shows the switching of expression of the mouse like globin genes during development. In addition, the graph also shows the pattern of
expression of the human -like globin genes when they are introduced into the mouse
as a YAC transgene. Adapted from Kim A, et al. Mol Cells. 2012, and Strouboulis J
et.al, Genes Dev. 1992. (B) The mouse -globin locus consists of three -like globin
genes: , 1 and 2 that display a developmental switch in expression. Adapted from
Vernimmen D, et al. EMBO J. 2007, and Palis J, et al. Int J Dev Biol. 2010.
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responsible for high-level transcription. These distal sequences are known as the locus
control region or LCR, located 6 to 20 kb upstream of the ε-globin gene, in the β-locus
and the multispecies conserved sequences or MSC, found 25 to 65 kb upstream of the
-locus (Higgs and Wood 2008; Stamatoyannopoulos 2005). The β-globin LCR was
discovered due to the presence of erythroid-specific and developmentally-controlled
DNaseI hypersensitive sites that were able to direct high-level human β-globin
expression in transgenic mice (Forrester et al. 1987; Grosveld et al. 1987). The LCR
consists of 5 such DNaseI hypersensitive sites (HS), designated 5’- HS1 to HS5, with
HS1 being the site nearest to the ε-globin gene. Each hypersensitive site is defined by a
core sequence of about 250 nucleotides and contains binding motifs for numerous
transcription factors. The LCR can activate the expression of only one gene at a time
(Wijgerde, Grosveld, Fraser 1995). The LCR is postulated to enhance globin gene
expression by interacting with the promoter of the gene through looping, as evidenced
by crosslinking of juxtaposed DNA sequences in 3C assays (Fig 1.7) (Tolhuis et al.
2002).

1.3 Hemoglobinopathies
Hemoglobinopathies or the disorders of hemoglobin are some of the most
common genetic disorders in the world, with approximately 5% of the world’s population
carrying a significant variant (WHO statistics). They result from abnormalities in either
the structure or production of hemoglobin. β-hemoglobinopathies are of two main types:
sickle cell disease and β-thalassemia.
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Figure 1.7: Looping between the LCR and the globin gene promoters at the globin chromatin hub. Adapted from Kim A, et al. Mol Cells. 2012 (Kim and Dean
2012)

Figure 1.8: Sickle shaped red blood cells are seen in sickle cell anemia. Arrows
point to sickle RBCs. Adapted from American Society of Hematology image bank
(Author: Stanley Schrier)
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1.3.1 Sickle cell anemia
Pathophysiology: Sickle cell anemia is caused by a point mutation in the adult β-globin
gene that causes the substitution of a glutamic acid residue by a valine at the 6 th amino
acid position in the β-chain. The resulting mutant β-chain is denoted βS and hemoglobin
molecules that contain these chains are called sickle-hemoglobin or HbS (2βS2). In lowoxygen conditions, HbS molecules have a tendency to polymerize within erythroid cells
and distort the shape of the erythroid cell from its typical discoidal shape to a sickle
shape, giving the disease its name (Fig 1.8). The sickle shaped cells cannot pass
through small capillaries with the same ease as normal erythroid cells and thus they
cause occlusions in these vessels, which results in a painful condition termed sickle cell
crisis. The abnormal shape of sickle cells also targets them for destruction, resulting in
anemia.
Prevalence: Sickle cell anemia is an autosomal recessive disorder. People who have
one abnormal β-globin gene are said to have sickle cell trait and are asymptomatic. The
highest prevalence of sickle cell anemia is in Africa, Central and South America, the
Mediterranean countries, India and Saudi Arabia. It is estimated that sickle cell anemia
affects approximately 100,000 Americans. Disease occurrence is estimated at about 1
in every 500 African American births and 1 in 36,000 Hispanic American births.
1.3.2 β-thalassemia
Pathophysiology: β-thalassemia is caused by decreased (β+) or absent (β0) production
of adult β-globin which results in very low levels or a complete lack of HbA. There is a
concurrent accumulation of the excess -globin chains, which precipitate in cells and
cause cellular toxicity. Decreased β-globin production is caused by mutations and
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deletions of the β-globin gene and its proximal cis-regulatory elements as well as by
mutations in genes encoding trans-regulatory factors such as transcription factors
essential for globin gene expression. Clinical symptoms of the disease vary based on
residual amounts of β-globin and are classified into three groups:
1. β-thalassemia minor: Individuals who are heterozygous for a mutation in the βglobin gene (β+/β or β0/β) and have mild microcytic anemia.
2. β-thalassemia intermedia: Individuals who still produce some β-globin (β+/β+ or
β0/β+) and have moderate disease severity with varying needs for blood
transfusions.
3. β-thalassemia major: Individuals who do not produce any β-globin (β0/β0) and
have severe microcytic, hypochromic, transfusion-dependent anemia.
Prevalence: The highest occurrence of β-thalassemia is observed in the Mediterranean
and Middle Eastern countries, southern Asia including India, China and the Far East
and northern Africa.
1.3.3 Treatment of β-hemoglobinopathies
Current treatments for sickle cell anemia and β-thalassemia are aimed at
management of the disease through alleviation of its symptoms. The only cure available
for some patients is through bone marrow transplantation from a closely matched donor.
Finding such a donor is rare. In addition, the high level of associated risk and the cost
involved limit the accessibility of this form of treatment (Sankaran and Nathan 2010).
Thus there is no widely available curative approach for either sickle cell anemia or βthalassemia.
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Treatment of sickle cell anemia aims at management of disease symptoms
including pain relief, prevention of infections, organ damage and complications. Many
sickle cell anemia patients require frequent blood transfusions to treat anemia and
prevent conditions such as stroke. Treatment of β-thalassemia major also involves
frequent blood transfusions and monitoring of hemoglobin levels. While blood
transfusions allow the affected individuals the ability to lead a more normal life, they are
associated with the risk of transmitted infections and have serious side effects including
severe iron overload. Advances in iron chelation therapies that remove excess iron from
the body have tremendously improved the odds for patients in need of constant
transfusions.
Although in most people fetal hemoglobin (HbF) levels decline after birth to less
than 2% of total hemoglobin, certain people exhibit constantly elevated levels of HbF
throughout their life, an asymptomatic condition known as Hereditary Persistance of
Fetal Hemoglobin (HPFH) (Forget 1998). It was observed in clinical evaluations that βthalassemia patients who had elevated levels of fetal hemoglobin (HbF) manifested less
severe disease symptoms (Weatherall 2001), suggesting that re-expression of -globin
in adult cells can surmount the lack of β-globin. This finding prompted many
investigators in the globin field to look for chemical agents capable of inducing the
expression of fetal hemoglobin in adult erythroid cells. The earliest of these studies led
to the discovery and implementation in treatment regimens of a drug called
hydroxyurea, an S-phase inhibitor (Letvin et al. 1984; Platt et al. 1984). The use of
hydroxyurea in treating sickle cell disease was discovered through studies of 5azacytidine, a carcinogenic, demethylating agent, that elevated the levels of fetal
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hemoglobin in baboons (DeSimone et al. 1982). The mechanism by which hydroxyurea
elevates fetal hemoglobin is not entirely known, although it is speculated that
hydroxyurea may stimulate stress erythropoiesis pathways. Hydroxyurea has not
proved an equally effective treatment for β-thalassemia (Alebouyeh et al. 2004). Thus
the search is still on for pharmacological inducers of fetal hemoglobin. An ideal
candidate for treatment should have the following attributes: 1. It should elevate HbF in
adult erythroid cells 2. It should not adversely affect erythropoiesis 3. It should
preferably act specifically in erythroid cells so as not to affect other hematopoietic / nonhematopoietic lineages 4. It should have minimal side effects. A better understanding of
the molecular regulators of -globin expression and the underlying mechanisms will
undoubtedly accelerate the achievement of this goal.

1.4 Model systems for studying erythropoiesis and globin gene regulation
The knowledge that we have gained thus far about the processes and factors
that govern erythropoiesis come from the assimilation of data from studies in numerous
model systems. Outlined below are the salient features of some of the more commonly
used model systems. Each system has its advantages and drawbacks. No model
system in isolation can satisfactorily and conclusively provide answers to all our
questions with regards to development and its molecular regulators. However,
information pieced together from the combination of multiple model systems has
substantively furthered our understanding of developmental biology.
1.4.1 Immortalized cell lines
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K562 cell line: K562 is a human erythroleukemia cell line that was established from the
pleural effusion of a chronic myelogenous leukemia patient in blast crisis (Lozzio and
Lozzio 1975). Cytogenetic studies showed that these cells have the Philadelphia
chromosome and other chromosomal aberrations. K562 cells are widely used to study
erythropoiesis since they are easy to grow in a suspension culture, represent a human
model, show certain features of erythroblasts and can be induced by hemin treatment to
express embryonic and fetal hemoglobins (Koeffler and Golde 1980). The major
drawback of this cell line is that since it is a leukemia cell line, it is difficult to tease out
effects that are downstream of the various chromosomal aberrations.
Mouse erythroleukemia (MEL) cell line: This cell line was derived by immortalization of
mouse splenic cells by infection with a virus (FRIEND 1957). MEL cells are erythroid
progenitor cells that can be induced to differentiate into erythroid cells by treatment with
dimethyl sulfoxide (DMSO) (Antoniou 1991; Friend et al. 1971). They are grown in
suspension culture and express mouse adult hemoglobin (2βmaj2) upon DMSO-induced
differentiation.
1.4.2 Transgenic globin mice
Erythroid cells mature in very specialized environments within organisms. Since
cells grown in culture lack interactions with these developmental niches, it is difficult to
study many aspects of erythroid differentiation in tissue culture systems. In order to
circumvent this issue and study regulation of the human globin genes in an in vivo
system, transgenic mice were developed that carry the entire human β-globin locus.
Mice are an attractive model system due to their relatively short gestation period and
because erythropoiesis in mice closely mirrors that in humans. The first β-locus
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transgenic mice were developed using strategies to ligate two cosmid constructs
(Strouboulis, Dillon, Grosveld 1992). The use of yeast artificial chromosomes (YAC)
enabled researchers to develop transgenic mice with YACs that could incorporate larger
DNA fragments than previously available vectors. In this manner, transgenic mice
carrying 150-250 kb YACs spanning the entire human β-globin locus and flanking
regulatory sequences were generated (Gaensler, Kitamura, Kan 1993; Peterson et al.
1993). The mice are referred to as the β-YAC transgenic mice. β-YAC mice express the
human globin genes in a tissue- and developmental-stage specific manner that
resembles the expression of the endogenous mouse genes (Fig 1.6 A). The human εand -globin genes are expressed in yolk sac erythroid cells and the human β-globin
gene is expressed in fetal liver-derived and bone marrow-derived erythroid cells. The βYAC mice have been instrumental in studying numerous aspects of globin gene
regulation in vivo. The major drawback of this model is that human -globin is expressed
as an embryonic gene similar to the mouse embryonic genes, and not as a fetal gene,
thus deviating from its expression pattern in humans.
1.4.3 Primary human cell lines
In the last decade, researchers have refined methods of primary human cell
culture in order to obtain large numbers of erythroid cells from relatively few CD34+
hematopoietic precursor cells obtained from adult blood or bone marrow and umbilical
cord blood (Migliaccio et al. 2002). The development of these methods have enabled
the study of various aspects of erythropoiesis in primary human cells unobstructed by
the effects of immortalization that were present in previously available cell lines. A
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detailed description of how these cells are isolated, cultured and manipulated is
presented in the methods section of this dissertation.

1.5 Molecular regulators of erythropoiesis and hemoglobin switching
Research has led to the identification and characterization of numerous
transcription factors, both erythroid specific, and more generally expressed, which play
important roles in establishing and maintaining an erythroid fate. Some of these factors
have dual roles in regulating various aspects of erythroid cell maturation as well as
globin gene expression. Others are particularly required for either expression or
silencing of the stage specific globin genes in a timely manner. Substantial effort has
been devoted to identification and characterization of various repressive complexes that
silence -globin expression in adult erythroid cells, with the aim of using this information
to develop therapeutic strategies to re-express -globin in adult erythroid cells
(Sankaran and Orkin 2013). Less is known about the factors necessary for activation of
-globin expression in fetal erythroid cells. A list of some of the factors that have known
roles in either activating or silencing -globin expression are presented in Table 1.1.
Described below are some of the pivotal players of the complex transcriptional network
that controls the process of erythropoiesis.
1.5.1 SCL / Tal1 and LMO-2
SCL/Tal1 and LMO-2 are transcription factors necessary for the development of
primitive erythropoiesis. SCL/Tal1 is a basic helix-loop-helix transcription factor
expressed in hematopoietic progenitor cells as well as in primitive and definitive
erythroid cells, mast cells and megakaryocytes (Robb and Begley 1997). SCL knockout
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Table 1.1. A partial list of regulators of -globin expression
Human
genetic
evidence
supporting
role in HbF
regulation

Human or
primate
studies
modulating
factor
involved in
HbF
regulation

Cell culture
data
supporting a
role in HbF
regulation

Evidence
from mouse
models
suggesting a
role in HbF
regulation

Regulator

Direction of
modulation
needed to
increase HbF

BCL11A

↓

×

×

×

KLF1

↓

×

×

×

MYB

↓

×

×

MicroRNAs
15a/16-1

↑

×

×

SOX6

↓

HDACs 1/ 2

↓

×

×

×

DNMT1

↓

×

×

×

TR2/TR4

↓ or ↑

×

×

COUP-TFII

↓

×

FOP

↓

×

NF-E4

↑

×

×

Adapted from Sankaran, et al. CSHP Med 2013.
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mice are embryonic lethal and die by E9.5 (Robb et al. 1995). They display a total lack
of primitive erythropoiesis, with no discernable blood islands and a failure to produce
hematopoietic colonies in colony formation assays. LMO-2 is a LIM domain containing
transcription factor. LMO-2 is greatly expressed in the fetal liver of mouse embryos, as
well as in the brain and spleen. It is present in both primitive and definitive erythroid
cells and absent in cells of other hematopoietic lineages (Warren et al. 1994). LMO-2
knockout mice are embryonic lethal and die around E10.5. LMO-2-/- embryos are pale
in appearance at E9.75 and lack circulating erythroid cells. They also do not produce
erythroid colonies in colony forming assays, indicating a defect in establishment of the
primitive erythroid lineage.
1.5.2 Gata1 and Gata2
Gata1 and Gata2 are members of the GATA family of Cys2-Cys2 zinc finger
transcription factors. They recognize and bind to the consensus DNA sequence
WGATAR. Gata1 and Gata2 are required for mouse viability. Gata1-/- embryos are pale
in appearance at E9.5 and die between E10.5 and E11.5 (Fujiwara et al. 1996).
Primitive erythroid cells are present in Gata1-/- embryos, but they show defects in
maturation and are arrested at the proerythroblast stage of development. Gata1-/embryos produce definitive erythroid colonies in colony formation assays, but the cells
in these colonies are arrested at the proerythroblast stage. Thus Gata1 is required for
terminal maturation of both primitive and definitive erythroid cells. Gata2-/- embryos die
between E10-E11 and are severely anemic (Tsai et al. 1994). The number of circulating
erythroid cells is drastically reduced in E9.5 Gata2-/- embryos, but their maturation is
not affected. In vitro differentiation of Gata2-/- ES cells showed that absence of Gata2
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greatly impairs development of primitive and definitive erythroid colonies as well as
macrophage and mast cell colonies, indicating a defect at the level of hematopoietic
stem or progenitor cells. Further investigation revealed that Gata2 is required for the
expansion of multipotent hematopoietic progenitors (Tsai and Orkin 1997). Combined
absence of Gata1 and Gata2 in Gata1/Gata2 double knockout mice results in a
complete loss of the primitive erythroid compartment at E8.5 (Fujiwara et al. 2004).
1.5.3 Runx1 and c-myb
Runx1 and c-myb are transcription factors that are critical for definitive
erythropoiesis but not for primitive erythropoiesis. Runx1 (also known as CBFA2 or
AML1) codes for the DNA-binding subunit of core binding factor (CBF). Runx1-/embryos die by E12.5 and are unable to produce both definitive erythroid and myeloid
colonies in colony forming assays (Wang et al. 1996). Primitive erythropoiesis appears
to proceed normally with mild morphological defects in a small fraction of cells
(Yokomizo et al. 2008). C-myb, initially identified as a proto-oncogene, is a transcription
factor with pronounced expression in erythroid, myeloid and lymphoid progenitor cells
(Mucenski et al. 1991). C-myb-/- embryos develop severe anemia around E15. Primitive
erythropoiesis is unaffected in c-myb-/- embryos. Peripheral blood of E15 c-myb-/embryos contains mostly primitive erythroid cells and very few definitive erythroid cells
whereas the opposite is true for wild-type littermates. C-myb-/- fetal livers showed
hypocellularity and colony forming assays indicated a drastic reduction in the number of
multipotent hematopoietic progenitors, demonstrating that c-myb is essential for
definitive erythropoiesis.
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1.5.4 Krüppel-like factors (KLFs)
The Krüppel-like factors (KLFs) are a family of Cys2-His2 zinc finger transcription
factors, named for the Drosophila protein Krüppel with which they share homology.
Each KLF consists of a C-terminal DNA binding domain made up of three zinc fingers
and an N-terminal transactivation domain (Fig. 1.9). Since the DNA binding domain of
all KLFs are extremely similar to each other they recognize and bind to a common
consensus sequence, 5’-CACCC-3’, in DNA. While some KLFs show tissue restricted
expression patterns, others are ubiquitously expressed. To date, 17 Krüppel-like factors
have been discovered with a wide range of roles in development and homeostasis (Fig.
1.10) (McConnell, Physiol Rev 2010). Of these, KLF1, KLF2, KLF3 and KLF8 have
known roles in erythropoiesis. KLF1 and KLF2 are discussed in detail since they are
central to the research presented in this dissertation.

Figure 1.9: Krüppel-like factors are defined by an N-terminal transactivation
domain and a C-terminal DNA binding domain made up of three C2H2 zinc
fingers.
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Figure 1.10: Phylogenetic mapping of members of the Krüppel-like family of
transcription factors.
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KLF1
Krüppel-like factor 1 (KLF1) or erythroid Krüppel-like factor (EKLF) was first
isolated from MEL cells, by the technique of subtractive hybridization to identify genes
preferentially expressed in erythroid cells (Miller and Bieker 1993). The mouse KLF1
protein is 376 amino acids long and contains three Cys2-His2 zinc fingers near its
carboxy-terminal (Miller and Bieker 1993). These zinc finger domains share strong
homology with the zinc fingers of the Drosophila gene Krüppel and hence this factor
was named erythroid Krüppel-like factor (EKLF). The zinc fingers recognize the 9 bp
sequence, 5’- CCM-CRC-CCN -3’, and mediate binding of KLF1 to DNA (where R
represents A or G and M represents A or C) (Feng, Southwood, Bieker 1994; Miller and
Bieker 1993; Tallack et al. 2010).
KLF1 mRNA expression is first detected at E7.5 in the extraembryonic
mesoderm of the mouse visceral yolk sac, coincident with the earliest stages of blood
island formation (Southwood, Downs, Bieker 1996). KLF1 protein is present in both
primitive and definitive erythroid cells in embryos (Southwood, Downs, Bieker 1996).
KLF1 expression is up-regulated in primitive erythroid cells between E8.5 and E9.5 and
remains high between E9.5 and E11.5, followed by a decline at E12.5 (Isern et al.
2010). KLF1 shows robust expression in fetal liver definitive erythroid cells with 3-fold
higher protein amount in definitive compared to primitive cells (Alhashem et al. 2011;
Zhou et al. 2006). In adult mice, KLF1 mRNA expression is restricted to bone marrow
and spleen tissue (Miller and Bieker 1993). KLF1 is expressed in hematopoietic cells
prior to erythroid commitment (Frontelo et al. 2007). KLF1 expression is detected at low
levels in multipotent hematopoietic progenitors (MPP) and common myeloid-erythroid
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progenitor (CMP) and at higher levels in the common megakaryocyte-erythroid
progenitor (MEP) (Frontelo et al. 2007; Lohmann and Bieker 2008). Onset of KLF1
expression is regulated by Gata2 and Smad5 (Lohmann and Bieker 2008). It has also
been shown that GATA-1 and CCAAT-binding protein 1 (CP1) bind to and transactivate
the KLF1 promoter in MEL cells (Crossley et al. 1994).
KLF1 has emerged as a key regulator of almost all aspects of erythrocyte
development (Fig. 1.11). Two research groups independently developed KLF1 knockout
mice by gene targeting strategies (Nuez et al. 1995; Perkins, Sharpe, Orkin 1995).
KLF1 heterozygous mice survive to adulthood and appear normal. KLF1 knockout mice
die in utero by E16. E15 KLF1-/- embryos show decreased hematocrit and hemoglobin
content. Definitive erythroid cells from E15 KLF1-/- embryos are abnormal in
appearance and have reduced amounts of β-globin mRNA and protein compared to
wild-type littermates (Perkins, Sharpe, Orkin 1995). Primitive KLF1-/- erythroid cells
show dysregulation of the embryonic βh1- and εy-globin genes and abnormal cellular
morphology (Basu et al. 2007; Hodge et al. 2006). In addition to the β-like globins, KLF1
regulates the expression of numerous other erythroid genes, including those encoding
cytoskeletal and membrane proteins, and heme synthesis enzymes (Drissen et al.
2005; Hodge et al. 2006; Nilson et al. 2006; Pang et al. 2012).
Primitive and definitive KLF1-/- blood cells show cell cycle defects (Pilon et al.
2008; Tallack et al. 2009). At E13.5, wild-type fetal livers consist predominantly of R3R5 erythroid cells, and a small fraction of R1-R2 erythroid cells. In contrast, KLF1-/- fetal
livers consist almost entirely of R1-R2 early erythroid progenitors, demonstrating a role
for KLF1 in terminal erythroid differentiation in definitive erythroid cells
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Figure 1.11: KLF1 regulates numerous aspects of erythroid cell development.
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(Pilon et al. 2008). Gene expression profiling studies suggested that this maturation
defect stemmed from aberrant regulation of genes that control cell cycle progression in
KLF1 knockouts. It has been shown that KLF1 directly regulates cell cycle genes, E2f2
and p18INK4c (Pilon et al. 2008; Tallack, Keys, Perkins 2007; Tallack et al. 2009).
Furthermore, both primitive and definitive KLF1-/- erythroid cells display hampered G1to S-phase cell cycle progression (Pilon et al. 2008; Tallack et al. 2009).
Studies using β-YAC mice showed that there was a decrease in human β-globin
mRNA amount and elevated -globin mRNA expression in compound KLF1+/-, β-YAC
transgenic and KLF1-/-, β-YAC transgenic fetal livers (Perkins, Gaensler, Orkin 1996;
Wijgerde et al. 1996), suggestive of competition between the  and β genes. However,
β-globin expression was normal and the -globin gene was silenced in adult KLF1+/mouse blood (Wijgerde et al. 1996). Changes in - and β- globin gene expression
correlate with the percentage of transcriptionally active genes suggesting that changes
in expression are not due to changes in rates of transcription (Wijgerde et al. 1996). In
addition, loss of DNaseI hypersensitivity was observed at the β-globin promoter and
partial loss was observed at HS3 of the LCR in KLF1-/- fetal livers, suggesting that
KLF1 is required for normal chromatin configuration (Wijgerde et al. 1996).
In primitive erythroid cells, KLF1 binds to the hypersensitive sites of the LCR,
HS1-4, and to the promoters of the εy-, βh1, and βmaj-globin genes (Alhashem et al.
2011; Zhou et al. 2006). This was a surprising discovery since βmaj-globin is expressed
at very low levels in primitive erythroid cells. In definitive erythroid cells from fetal liver
and bone marrow, KLF1 binds to HS1, HS2, HS3, HS4 and the adult βmaj-globin
promoter but not to the embryonic εy- and βh1-globin promoters (Zhou et al. 2006).
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Chromatin conformation capture (3C) experiments in wild-type mouse E12.5 fetal liver
cells have indicated that the βmaj promoter lies in close proximity to the LCR and the
distal 5’HS-62 site in these cells in which the βmaj gene is actively transcribed (Drissen
et al. 2004). These locus interactions are severely affected in KLF1-/- fetal livers and
are dependent on the presence of KLF1 but not on downstream protein synthesis
(Drissen et al. 2004). Thus KLF1 is required for the formation / stabilization of an active
chromatin hub (ACH) at the β-globin locus.
Co-transfection experiments revealed that KLF1 protein interacts with three
histone acetyl transfersases (HATs), p300, CBP and P/CAF (Zhang and Bieker 1998).
CBP and p300 can acetylate KLF1 in vitro and enhance its trans-activation ability in
K562 cells (Zhang and Bieker 1998). Histone H3 acetylation and NF-E2 (p45) binding
was decreased at HS2 of the LCR and human β-promoter in KLF1-/- hematopoietic
progenitor cells from β-YAC transgenic mice (Bottardi et al. 2006). There was also
decreased CBP and BRG1 binding to huβ promoter but not to HS2 in KLF1-/hematopoietic progenitor cells (Bottardi et al. 2006). In E13.5 fetal liver erythroid cells
there was decreased binding of NF-E2 (p45), CBP and BRG1 at HS2 of the LCR and
human β-promoter in KLF1-/- compared to wild-type (Bottardi et al. 2006).
Actively transcribed genes show preferential intra- and inter-chromosomal coassociations in the nucleus, and the majority of these associations occur within
transcription factories that are enriched for RNAPolII-S5P. The β-globin genes display
such intra- and inter-chromosomal co-associations with other erythroid-expressed
genes in mouse erythroid cells (Schoenfelder et al. 2010). Transcription-related
chromosomal interactions between genes that are regulated by KLF1 were shown to be
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dependent on KLF1 (Schoenfelder et al. 2010). In addition to decreased interchromosomal associations, KLF1 regulated genes also showed decreased transcription
factory occupancy in KLF1-/- erythroid cells (Schoenfelder et al. 2010). Thus KLF1 is a
“global” regulator of erythroid gene expression.
KLF2
KLF2, also known as lung Krüppel-like factor or LKLF, was discovered due to the
similarity of its zinc finger domain to that of KLF1 (Anderson et al. 1995). KLF2 is a 354
amino acid protein in mice and a 355 amino acid protein in humans, with a predicted
mass of 37.7 KDa. Within the zinc finger region, KLF1 and KLF2 are 88% homologous
to each other. However, outside this region, they share little homology. Due to their
highly homologous zinc finger domains, KLF1 and KLF2 are predicted to bind to the
same / extremely similar DNA sequences. In addition, KLF2 also contains a 5’ prolinerich putative transactivation domain region, similar to KLF1. The KLF2 protein is
modular in nature with transactivation potential localized to amino acids 1-110,
functionally separable from its zinc finger domain. Amino acids 111-267 of KLF2 confer
an inhibitory effect to its transactivation ability (Conkright, Wani, Lingrel 2001). Evidence
suggests that, analogous to KLF1 - CBP/p300 interactions, KLF2 interacts with
CBP/p300 and this interaction has functional consequences (SenBanerjee et al. 2004).
Human and mouse KLF2 proteins share 90% amino acid similarity (Wani et al.
1999). Of interest is the observation that the proximal promoter regions of human and
mouse KLF2 also share an identical sequence of 75 bp near the transcription start site,
suggesting that KLF2 may be similarly regulated in both organisms. Studies of the KLF2
promoter region showed that the -243 to -72 bp region upstream of the transcription
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start site was required for robust reporter gene expression (Schrick et al. 1999). This
172 bp fragment contains two Sp1 binding sites, which were found to only modestly
affect reporter gene expression. Linker scanning mutagenesis identified a 30bp
fragment from -138 to -111bp to be important for transcription of the KLF2 gene (Schrick
et al. 1999). Heterogeneous nuclear ribonucleoproteins (hnRNPs) hnRNP-U and
hnRNP-D, PCAF and p300 bind to this region and can activate transcription of KLF2 in
a macrophage cell line (Ahmad and Lingrel 2005). An upstream segment of the KLF2
promoter, from -1643 to -490bp, appears to possess repressive elements (Schrick et al.
1999).
KLF2 expression is detected early during mouse embryonic development, at E7,
using RNA prepared from whole embryos (Anderson et al. 1995). KLF2 is also
expressed in mouse ES cells and is important for their self-renewal capacity (Jiang et al.
2008). In the adult mouse, KLF2 expression is observed in lung, heart, spleen, skeletal
muscle and testis tissues (Anderson et al. 1995). At the cellular level, KLF2 is
expressed in erythroid, endothelial, CD4+ and CD8+ quiescent T-cells and bone
marrow macrophages (Kuo, Veselits, Leiden 1997; Kuo et al. 1997; Zhang et al. 2005).
Two groups independently developed KLF2-/- mice using gene targeting
strategies (Kuo et al. 1997; Wani, Means, Lingrel 1998). KLF2+/- mice are
phenotypically normal. KLF2 knockout mice are embryonic lethal and die between
E11.5 and E14.5 (Chiplunkar et al. 2013; Kuo et al. 1997; Wani, Means, Lingrel 1998).
Death of embryos is due to heart failure (Lee et al. 2006). Haemorrhaging has been
observed in KLF2-/- embryos between E12.5 and E14.5 by some groups but not by
others (Kuo et al. 1997; Lee et al. 2006). Detailed studies of mice lacking KLF2 in
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specific cell types, revealed multiple roles for KLF2 in different tissues. KLF2 is essential
for maintenance of the quiescent state of mature, single positive T-cells (Kuo, Veselits,
Leiden 1997). KLF2-/- embryos show abnormalities in vascular tunica media
development (Kuo et al. 1997). A role for KLF2 in normal lung development was
demonstrated when KLF2-/- mouse embryonic stem cells used to generate chimeric
mice contributed to all other organ systems except the lung (Wani, Wert, Lingrel 1999).
Animals in which the KLF2-/- ES cells contributed to formation of the lungs died at birth,
with deficient lung development (Wani, Wert, Lingrel 1999). KLF2 expression is induced
in endothelial cells in response to fluid shear stress, where it is considered to have an
atheroprotective effect (Atkins and Jain 2007; Dekker et al. 2002).
We are particularly interested in the role of KLF2 in erythroid cells. Early studies
indicated that KLF2 can transactivate reporter gene expression downstream of the
human - and β-globin gene promoters in in vitro assays (Anderson et al. 1995; Zhang
et al. 2005). Studies using KLF2 knockout mice showed that KLF2 regulates the mouse
embryonic β-like globin genes, εy- and βh1-globin, but not the adult βmaj- and βminglobins (Basu et al. 2005). There is an approximate 2-fold decrease in εy- and βh1globin mRNA amount at E10.5 in KLF2-/- yolk sacs compared to wild-type. No change
was observed in adult βmaj- and βmin-globin gene expression in E12.5 fetal livers of
KLF2-/- embryos compared to wild-type. Compound β-YAC transgenic / KLF2 null mice
were used to determine whether KLF2 regulates the human β-like globin genes. Human
embryonic ε-globin mRNA amount was decreased in KLF2-/- mice compared to wildtype in this model. Expression of human fetal -globin mRNA in the yolk sac and adult
β-globin mRNA in the fetal liver were unaffected. In addition to the observed changes in
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globin gene expression, E10.5 KLF2-/- circulating erythroid cells show morphological
abnormalities with irregular cell membranes showing attenuated cytoplasmic processes.
KLF2-/- embryos also have a higher percentage of apoptotic primitive erythroid cells
compared to wild-type (Basu et al. 2005). KLF2-/- E11.5 fetal livers produce fewer CFUE than wild-type, by in vitro erythroid colony formation assays, indicating that KLF2 may
play a role in definitive erythropoiesis (Wani, Means, Lingrel 1998).
KLF1 and KLF2 gene interactions
The

Krüppel-like

factors

KLF1

and

KLF2

are

essential

for

primitive

erythropoiesis. Previous work in our lab has revealed that KLF1 and KLF2 display
overlapping roles in many facets of primitive erythropoiesis (Basu et al. 2007).
KLF1/KLF2 double knockout embryos have a significantly greater reduction in mouse
embryonic Ey- and βh1-globin mRNA at E10.5 than either of the single knockouts. The
KLF1/KLF2 double knockout embryos die earlier than either of the single knockouts and
are severely anemic in comparison to the visibly normal appearance of KLF1-/- and
KLF2-/- embryos (Fig. 1.12). They show a more severe phenotype with regards to
erythroid cell morphology and global gene expression, indicating that KLF1 and KLF2
can partially compensate for each other (Basu et al. 2007; Pang et al. 2012). KLF1 has
an erythroid specific pattern of expression whereas KLF2 is expressed in many tissues
including the lung, lymphocytes, erythroid and endothelial cells. Conditional knockout
mouse experiments have demonstrated that the effect of KLF2 on mouse embryonic
globin gene expression is erythroid cell-autonomous (Alhashem et al. 2011).
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Figure 1.12: E10.5 KLF1-/-KLF2-/- embryos are severely anemic. (A) and (B) E10.5
whole mounts of wild-type embryos surrounded by and dissected out of the yolk sac
respectively. (C) and (D) E10.5 KLF1-/-KLF2-/- whole mount embryos surrounded by
and dissected out of the yolk sac respectively. Adapted from Basu P, et al. Blood 2007.
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Other KLFs
In addition to KLF1 and KLF2, KLF3 and KLF8 have also been shown to have
roles in erythropoiesis. KLF3 and KLF8 are transcriptional repressors (Suzuki et al.
2005). KLF3-/- mice are viable, have a mildly anemic phenotype and show
reticulocytosis and the presence of abnormal erythroid cells in peripheral blood (Funnell
et al. 2012; Sue et al. 2008). KLF8-/- mice are viable and have normal blood counts
(Funnell et al. 2013). It was observed that KLF1 positively regulates KLF3 and KLF8 in
erythroid cells, whereas KLF3 represses KLF8, forming a transcriptional network that
may be important for the normal progression of erythropoiesis (Eaton et al. 2008;
Funnell et al. 2007).

1.5.5 BCL11A
Genome wide association studies have recently identified SNPs in the BCL11A
gene that correlate with elevated fetal hemoglobin (HbF) in adults (Menzel et al. 2007).
Further investigation has shown that stable knockdown of this zinc finger transcription
factor in erythroblasts derived from CD34+ human hematopoietic progenitors results in
a 3- to 6-fold increase in -globin mRNA (Sankaran et al. 2008). BCL11A binds to HS3
of the β-globin LCR as well as to two sites in the - intergenic region, but not to the
promoters of any of the β-like globin genes (Sankaran et al. 2008). 3C assays using
fetal liver cells from BCL11A-/- βYAC transgenic mice showed a decreased frequency of
loop formation between the LCR and the β-globin gene and slight increase in the
frequency of looping between the LCR and -globin gene (Xu et al. 2010). These results
suggest that BCL11A may be a repressor of -globin expression and play a role in the -
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to β-globin switch. KLF1 positively regulates BCL11A expression in mouse and human
definitive erythroid cells and there is evidence suggesting that this may be a direct effect
(Borg et al. 2010; Zhou et al. 2010).

Rationale
Hemoglobinopathies currently affect millions of people and represent a growing
disease burden worldwide with an estimated 300,000 to 400,000 affected babies born
each year (Williams and Weatherall 2012). However, affected patients still lack a widely
applicable and easily available cure. Research in the field has been geared towards the
elucidation of molecules and mechanisms that control hemoglobin switching, with the
aim of re-expressing -globin in patients with -hemoglobinopathies. In order to achieve
this goal, it is imperative that we gain a better understanding of two important aspects of
normal -globin gene regulation: (1) activation of gene expression or the mechanisms by
which the -globin gene is turned on in the fetus and (2) repression of gene expression
or the mechanisms by which the -globin gene is silenced in adults. A composite
approach that manipulates both these complimentary regulatory mechanisms will likely
produce the most effective therapeutic strategy.
A large portion of effort in the field has been devoted to studying derepression of
the silenced -globin gene in adult erythroid cells and the factors that control repressive
mechanisms. These avenues have yielded certain candidates for therapeutic
intervention. However, factors involved in silencing of gene expression generally have
more global effects on gene expression in erythroid cells as well as other cell types,
which may cause unwanted side effects. In addition to releasing repressive

37

mechanisms it would be beneficial to simultaneously activate -globin expression by
modulating the levels of factors that positively regulate the -globin gene. There is a gap
in research with respect to factors that directly activate -globin expression in erythroid
cells. Evidence from studies in -YAC transgenic mice has shown that the Krüppel-like
factors KLF1 and KLF2 positively regulate -globin expression in embryonic erythroid
cells (Alhashem et al. 2011). Further, the KLF1 and KLF2 genes affect other aspects of
erythropoiesis in the mouse apart from globin gene regulation, individually and in
concert with each other. A holistic understanding of the functions of these factors in
erythroid cells is imperative before they are targeted for therapeutic applications.
KLF1 and KLF2 are essential for primitive erythropoiesis and previous work in
our lab using mouse KLF1/KLF2 double knockout embryos has revealed that KLF1 and
KLF2 display overlapping roles in many facets of primitive erythropoiesis (Basu et al.
2007). Simultaneous ablation of these factors results in a severely anemic embryonic
phenotype that is not evident in either KLF1 or KLF2 single knockout embryos (Basu et
al. 2007). In the first part of the following work, we aim to understand the cell
autonomous roles of KLF2 in erythroid cells and the extent of gene interactions between
KLF1 and KLF2 in primitive erythroid cells with an emphasis on elucidating the
mechanism of these interactions that cause anemia. These studies are carried out using
the mouse as a model system since it is not possible to study primitive erythropoiesis in
humans. In the second part of this study we employ the recently developed in vitro
system for culturing human erythroid cells derived from umbilical cord blood
hematopoietic progenitors as a “fetal” model to explore the role of KLF1 and KLF2 in
regulating the -globin gene in cells where -globin is actively expressed. Using this
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approach we aim to determine whether KLF1 and KLF2 positively regulate -globin
expression in human erythroid cells during development.
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Chapter 2: Methods

2.1 Studies in the mouse
2.1.1 Generation of mouse models
The KLF1 knockout (KO) mouse model was generated by targeted insertion of the
neomycin resistance gene (Fig. 2.1A) (Perkins, Sharpe, Orkin 1995). The KLF2 KO
mouse model was developed by interrupting the gene with the hypoxanthine
phosphoribosyl-transferase (Hprt) gene (Fig. 2.1B) (Wani, Means, Lingrel 1998). The
KLF1 and KLF2 loci are linked on mouse chromosome 8. This made it possible to
develop a model with the KLF1 and KLF2 null alleles on the same chromosome,
KLF1+/-KLF2+/-(R) (Basu et al. 2007). Mice with a floxed KLF2 allele were obtained
from Dr. Jerry Lingrel (Fig. 2.1B) (Weinreich et al. 2009). Mice carrying the KLF1 null
allele and the KLF2 floxed allele on the same chromosome were obtained by screening
for recombinants as previously described (Basu et al. 2007).The ErGFP-Cre mouse
model directs erythroid specific expression of the Cre gene (Cyclization recombinase)
under the control of the erythropoietin receptor (EpoR) promoter (Heinrich, Pelanda,
Klingmuller 2004). The Tie2-Cre mouse model directs erythroid- and endothelial-specific
Cre expression under the control of the Tie2 (endothelial-specific receptor tyrosine
kinase or Tek) promoter (Kisanuki et al. 2001).
2.1.2 Genotyping
Mice were genotyped using tissue obtained by ear-punching the mice at 3-4 weeks of
age. Ear clips were digested for 4-6 hours at 55-60°C in 50μl digestion buffer (10mMTris
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Figure 2.1: Graphical representation of wild-type and knockout alleles for KLF1
and wild-type, knockout and floxed alleles for KLF2. (A) Insertion of the neomycin
resistance gene (Neo) was used to disrupt the wild-type KLF1 allele. (B) The KLF2 gene
was targeted by insertion of the hypoxanthine phosphoribolsyl transferase (Hprt) gene.
The KLF2 floxed allele was generated by homologous recombination to incorporate two
LoxP sites flanking the second exon of KLF2. E – exon, WT – wild-type, Arrowheads –
LoxP sites, Red arrows – position of primers used for genotyping. Figure not drawn to
scale.
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HCL, pH8.5; 50mM KCl, 40mM MgCl2, 0.45% Tween 20 and 0.45% NP40) containing
1μg/μl proteinase K (Roche, PCR grade). Following digestion, proteinase K was
inactivated by 2 cycles of alternate boiling (>95°C) and cooling (4°C) for ten minutes
each. 1-2μl of the resulting lysate was used as the test DNA sample in a polymerase
chain reaction (PCR). The primers used for genotyping are listed in Table 2.1.
2.1.3 Tissue collection
Timed matings were used to obtain embryos at various developmental stages. The
observation of a vaginal plug was defined as embryonic day 0.5 (E0.5). Pregnant
female mice were sacrificed to obtain embryos between E8.5 and E10.5. Embryos were
dissected in PBS in petri dishes. Embryonic blood cells were collected by severing the
vitelline and umbilical vessels and allowing embryos to bleed into 1ml PBS in a 12-well
plate. The number of blood cells was counted using a hemocytometer and then cells
were processed for RNA preparation. Whole-mounts were photographed with an
Olympus SZ2-ILST (Olympus America, Center Valley, PA) microscope, using an
Olympus Q-Color 3 (Olympus America) camera and QCapture 2.81.0 software
(Quantitative Imaging, Surrey, BC). Mouse embryonic yolk sac was collected and
processed for embedding and sectioning. The embryo body was collected for
genotyping and processed similar to the ear clips, as described above.
2.1.4 RNA extraction and cDNA synthesis
Mouse embryonic blood cells, collected in PBS, were pelleted, resuspended in 200μl
denaturation solution (Totally RNA total RNA isolation kit, Ambion) and frozen at -80°C.
Post genotyping, samples of the required test and control genotypes were processed as
follows. Samples were thawed on ice. 3M sodium acetate (Totally RNA kit, Ambion) was
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added at 1/10th the volume of the sample, followed by 200μl of acid-phenol:chloroform
(pH 4.5,Totally RNA kit, Ambion). Samples were mixed by inverting the tubes 4-5 times
and centrifuged at 12,000g for 10 minutes at 4°C. The aqueous phase was transferred
to a fresh 1.5ml tube. 2μl of glycogen (5mg/ml stock, Ambion) was added to the
aqueous phase and mixed by pipetting. Then an equal volume of cold 100%
isopropanol was added to the sample and mixed by inverting the tubes 4-5 times. RNA
was allowed to precipitate overnight at -80°C. The following day, samples were thawed
on ice and centrifuged at 12,000g for 20-30 minutes at 4°C. The supernatant was
discarded, with care not to disturb the RNA pellet. The pellet was washed with 1ml of
cold 80% ethanol. The ethanol was discarded and the pellet was air-dried for 2-5
minutes on ice. The pellet was then resuspended in 10μl of RNase-free water (USB
Corporation) containing SuperaseIn (1:20 dilution, Ambion). 1μl of this sample was
further 1:10 diluted and used to determine RNA integrity and concentration using the
Agilent Bioanalyzer and the Agilent RNA 6000 Nano kit (Agilent Technologies),
following the manufacturer’s protocol. 500ng-1μg of RNA per sample was treated with
DNaseI (Life Technologies) and used to prepare cDNA following the instructions of the
iScript cDNA synthesis kit (Biorad). The cDNA thus obtained was diluted as required
and used to determine gene expression changes by quantitative reverse transcriptase
PCR (qRT-PCR).
2.1.5 Quantitative reverse transcriptase PCR (qRT-PCR)
Changes in gene expression were measured by quantitative PCR (qPCR) using cDNA
prepared as described above. Because cDNA is the template for this PCR, and it is
obtained by reverse transcription of RNA, this method is actually quantitative reverse
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transcriptase PCR (qRT-PCR), though it is abbreviated as qPCR herein. qPCR was
carried out using SYBR Green or Taqman reagent (Applied Biosystems) and plates
were run on an ABI Prism 7300 analyzer (Applied Biosystems). The absolute
quantification method was employed which measures the relative amount of amplified
product in a sample compared to a reference standard curve containing 5 known
quantities of cDNA ( expressed as the amount of RNA used for reverse transcription).
Stringent quality control measures are applied to all qPCR results. The R-value of the
standard curve must be >0.9. The amount of cDNA in all samples must fall within the
limits of the standard curve, i.e. sample readings must fall on the curve. Each sample is
run in quadruplets. At least three out of the four readings obtained for each sample must
be within 20% of the mean value for all four readings. Cyclophilin A or Gapdh mRNA
were used as internal standards for normalization as indicated in the figure legends.
Primer sequences used for qRT-PCR analyses of the mouse genes are listed in Table
2.2.
2.1.6 Plastic embedding and sectioning of yolk sac
Histological studies of the yolk sac were carried out by embedding the yolk sac in an
eponate resin with guidance and resources from Sue Walker in Dr. John Povlishock’s
lab (Dept. of Anatomy and Neurobiology). Briefly, yolk sacs were fixed in 2%
paraformaldehyde and 0.25% gluteraldehyde in Millonig’s buffer (Recipe) overnight at
4°C, rinsed 3 times and stored in Millonig’s buffer in the fridge. Post-genotyping, yolk
sacs of test and control genotypes were treated with 1% osmium tetroxide in Sorenson
buffer for 60 minutes at 4°C with gentle rocking, washed 3 times (5 minutes each) with
Millonigs buffer, followed by serial dehydration in 30%, 40%, 50%, 60% and 70%
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ethanol for 5 minutes each and 80%, 95% and 100% ethanol for 10 minutes each. Yolk
sacs were then incubated in a 1:1 mixture of 100% ethanol and propylene oxide for 5
minutes and propylene oxide alone for 2 changes of 10 minutes each, followed by resin
infiltration in a 1:1 mixture of eponate 12 and propylene oxide overnight with gentle
agitation inside a chemical hood. The following day the tissue was transferred to 100%
eponate 12 and kept on an agitator for 4 hours, and then transferred to the desired mold
containing 100% eponate 12 and incubated in a 55°C oven for 3 days for the resin to
solidify. Once the resin solidified, the block was trimmed and 2μm sections containing
the tissue were cut using glass knives and a Sorvall JB4 microtome. Sections were
placed on microscopy slides (Superfrost Plus slides, Fisher Scientific) in droplets of
water and kept on a hot plate to allow adhesion of tissue to the slide as the water
evaporates. Once dry, the slides were stained with warm methylene blue stain (1%
sodium borate, 1% azure II, 1% toluidine and 1% methylene blue). Sections were
mounted in oil using coverslips. Images of yolk sac sections were captured with an
Olympus BX41 compound microscope and Olympus DP71 digital camera.
2.1.7 Erythroid progenitor assays
To study primitive erythroid progenitors, E8.25 - E8.5 (6-12 somite pairs) implants
including embryo and yolk sac were dissected in PB2 (36). Embryonic tissues were kept
cold throughout the dissection procedure by placing them on a metal sheet in a tray
containing a mixture of ice and water. At the end of the dissection, each implant was
dissociated into single cells by incubating them at 37°C for a total of 20 minutes in 200μl
0.01% trypsin/ 1mM EDTA/ PBS (Worthington Biochemical Corporation, NJ) with
mechanical trituration at 10 minutes and 15 minutes. This process was carried out in a

45

96-well plate to monitor successful dissociation of implants. Once dissociated, 100μl of
IMDM containing 20% fetal bovine plasma derived serum (PDS, Animal Technologies,
TX) was added to arrest the action of trypsin. The cells were pelleted by centrifugation
(0.3rcf, 5 minutes, 4°C), resuspended in 200μl of 20% PDS in IMDM and counted using
a hemocytometer. Half of the cells from each implant (100μl) were added to 1.5ml of 1%
methylcellulose supplemented with 10% PDS, 5% protein-free hybridoma medium
(Gibco/BRL), IL-3 (20ng/ml), IL-6 (20ng/ml), stem cell factor (60ng/ml) (IL-3, IL-6 and
SCF – Peprotech, NJ), erythropoietin (2U/ml), MTG and L-glutamine in 1.5ml Eppendorf
tubes, vortexed and kept at room temperature for 15-20 minutes to allow bubbles to
surface (Table 2.3). Then 1ml of this medium containing cells was plated in 35mm petri
dishes and incubated at 37°C, 5% CO2. The remaining cells were used for genotyping.
Erythroid colonies were stained using benzidine and counted on either Day 2 or Day 6
of culture. The benzidine stock solution was made by dissolving 100mg benzidine
dihydrochloride in 50ml of 0.5% acetic acid. This stock can be stored in the dark at room
temperature for 6 months. When plates were ready to be stained, 5μl of 30% hydrogen
peroxide was added to 1ml of benzidine stock solution and 0.5 ml of this mixture was
immediately layered on the methylcellulose in the dish. Dishes were incubated with
stain for 15 minutes before counting colonies using an inverted microscope. Colony
images were captured using an Olympus IX70 microscope and Q-Color 3 camera
(Olympus America). Two dimensional colony areas were determined using Image J
software.
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2.1.8 Cell cycle analysis
Cell cycle profiles were assessed using the Allophycocyanin (APC) BrdU Flow kit (BD
Biosciences). The protocol was adapted from Malik et al. (37). Briefly, E9.5
erythroblasts were cultured in 500μl of erythroid maturation medium (see recipe below)
containing BrdU for 90 minutes (37°C, 5%CO2), followed by fixation (20minutes, room
temperature) and staining with APC-conjugated anti-BrdU antibody and 7-aminoactinomycin D (7-AAD), according to the manufacturer’s protocol (BD Biosciences).
After the final staining step, cells were resuspended in 200μl staining buffer and stored
overnight at 4°. The following day, the BD FACSCanto™ II Analyzer was used to
measure total DNA content and BrdU incorporation using 7-AAD and APC fluorescence
intensity, respectively. Gating was applied to include only single cells and exclude
clumped cells.

Maturation medium recipe: 10% serum replacement (Life Technologies), 10% PFHM-II
(Life Technologies), 2mM glutamax (L-alanyl-L-glutamine, Life Technologies), 150 μM
Monothioglycerol (MTG, Sigma), 1% fetal bovine plasma-derived serum (PDS, Animal
Technologies,Tyler, TX, USA), 1 U/ml recombinant human EPO (Amgen, Thousand
Oaks, CA, USA).
2.1.9 Statistical analysis
The Student’s t-test was used for statistical analyses. p values < 0.05 were considered
significant.
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Table 2.1: PCR primers used for genotyping mice
S.No.

Gene

Allele

Primer sequence 5’-3’

1

KLF1

WT

FP: GGT GAA CCC GAA AGG TAC
AA

Annealing
Temperature
°C
58

RP: CTG GGA CCT CTG TCA GTT
GC
KO

FP: GCC AGA GGC CAC TTG TGT
AG
RP: CTG GGA CCT CTG TCA GTT
GC

2

KLF2

WT

FP: TTG CCG TCC TTT GCC ACT
TTC G

58

RP: TTG TTT AGG TCC TCA TCC
GTG CCG
KO

FP: CGG TCT CTT GTA GCC AAA
GGG
RP: CCT ACC CGC TTC CAT TGC
TC

3

4

5

KLF2
(Same
primer set
for WT and
floxed
allele)

Floxed
allele

iCre
(ErGFPCre)

-

Cre
(Tie2-Cre)

-

FP: GGA GGT AGA CTT CAG GCT
GTG

61

RP: GTT GTT TAG GTC CTC ATC
CGT G
FP: TGT GGA TGC CAC CTC TGA
TGA AGT

60

RP: AGG GAC ACA GCA TTG GAG
TCA GAA
FP: GAA TCC TGG ATG CTA AGT TA
RP: AGT TCT GGA CAT GAT GAT A

48

60

Table 2.2: Primers for qRT-PCR analyses of mouse genes
S.No.

Gene

1

KLF2

Primer sequence 5’-3’
FP: CCAAGAGCTCGCACCTAAAG
RP: GTGGCACTGAAAGGGTCTGT

2

βh1-globin

FP: AGGCAGCTATCACAAGCATCTG
RP: AACTTGTCAAAGAATCTCTGAGTCCAT
Probe: AGAAACTCTGGGAAGGCTCCTGATTGTTTACC

3

Ey-globin

FP: CAAGCTACATGTGGATCCTGAGAA
RP: TGCCGAAGTGACTAGCCAAA
Probe: TCAAACTCTTGGGTAATGTGCTGGTGATTG

4

iCre
(ErGFP-Cre)

FP: CCTTTGAACGCACTGACTTTG
RP: GTCCTTCACTCTGATTCTGGC

5

Foxm1

FP: GGCAAAGACAGGAGAGCTATG
RP: TCTTCCAGTTCCTGCTTAACG

6

Cd24a

FP: CTTAGCAGATCTCCACTTACCG
RP: GTAAATCTGCGTGGGTAGGAG

7

Sphk1

FP: TGAATGGGCTAATGGAACGG
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RP: GTCTTCATTAGTCACCTGCTCG
8

Pthr

FP: CTAAGCTTCGGGAGACCAATG
RP: ACCGAAGAGTGGCACAAG

9

Gapdh

ABI Assay ID : Mm99999915_g1
(TaqMan® Gene Expression Assays)

10

Cyclophilin A

ABI Assay ID : Mm02342430_g1
(TaqMan® Gene Expression Assays)
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Table 2.3: Composition of medium for colony forming assay
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2.2 Studies using in vitro derived human erythroid cells
2.2.1 Isolation of human CD34+ hematopoietic progenitors from cord blood
Fresh umbilical cord blood (collected within 24-48 hours) was obtained from the St.
Louis Cord Blood Bank (SLCBB, St.Louis, MO). We usually receive 80-100ml of cord
blood. The cord blood is carefully transferred into 50ml centrifuge tubes and diluted 1:1
with DPBS. Diluted cord blood is layered on top of Ficoll-Paque™ Premium (GE
Healthcare) in the ratio 3ml Ficoll : 4ml cord blood in 50ml centrifuge tubes and
subjected to density gradient centrifugation and subsequent wash steps, according to
the manufacturer’s protocol, to obtain the mononuclear cells. After the final wash step
the mononuclear cells are resuspended in PBS containing 2% FBS and 1mM EDTA and
processed for isolation of CD34+ cells using the EasySep™ human CD34 positive
selection kit (Stem Cell Technologies) following the kit protocol. After the last wash step,
the cells obtained are resuspended in expansion medium (see recipe below) at a
density of 0.5-1 million cells per ml in 12 well plates and cultured at 37°C in a 5% CO2
incubator.
Expansion medium: StemSpan SFEM medium (Stem Cell Technologies) containing 1X
CC100 cytokine cocktail (Stem Cell Technologies), 8μl/ml LDL (Sigma, L7914) and 2%
Penicillin / Streptomycin (P/S, Gibco)
2.2.2 Expansion of CD34+ hematopoietic progenitors
Very few CD34+ hematopoietic progenitors are found in cord blood. On average, from
80-100ml of cord blood we obtain 0.5-2 million CD34+ cells after magnetic enrichment.
In order to have enough cells for various experimental endpoints, these CD34+ cells are
expanded for 7 days by culturing in expansion medium (see recipe above) in 12 well
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tissue culture plates and maintaining cell density at 1-2 million cells / ml. Cells were
counted and medium changed on alternate days.
2.2.3 Lentiviral infection of CD34+ hematopoietic progenitors
In order to manipulate the expression of our genes of interest, KLF1 and KLF2, in this
system, lentiviral vectors carrying either KLF1- or KLF2-targeted shRNA coding
sequences were either acquired from other labs or cloned. Two KLF1-targeted shRNA
vectors (pRRL_K1V1 and pRRL_K1V2) as well as a scrambled shRNA vector
(pRRL_Scr) were acquired from Dr. François Morlé (Université Claude Bernard Lyon1,
Lyon, France) and Dr. Fawzia Louache (INSERM, Villejuif, France). These vectors were
constructed on a pRRL backbone (Bouilloux, Blood 2008) with the shRNA-coding
sequence under the control of the H1 promoter. In addition to the shRNA-coding
sequence they carry a GFP-coding sequence, which aids in identification and recovery
of successfully infected cells by FACS. Sheng Zu Zhu from Dr. Gordon Ginder’s
laboratory (Virginia Commonwealth University) replaced the GFP gene in the pRRL
vector with an RFP gene. Five KLF2-targeted shRNA vectors were constructed by
cloning shRNA-coding sequences into the RFP-containing pRRL plasmid.
shRNA sequences aimed at targeting KLF2 mRNA were designed using software from
the following sources: Genelink (www.genelink.com), Whitehead institute siRNA
selection program (http://sirna.wi.mit.edu/, Bingbing, NAR 2004), Clonetech RNAi target
sequence selector (http://bioinfo.clontech.com/rnaidesigner/frontpage.jsp) and siDirect
(http://sidirect2.rnai.jp/design.cgi). shRNA sequences were shortlisted based on the
following rules: 1. There should be a G/C base at the 5’ end of the sense strand of the
shRNA 2. There should be an A/U at the 3’ end of the sense strand of the shRNA 3.
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Five out of the last seven bases at the 3’ end of the sense strand of the shRNA should
be A/U. For each shRNA, 4 oligonucleotides were synthesized (Eurofins MWG Operon)
according to the shRNA cassette design depicted in Fig.2.2. The oligonucleotide
sequences are listed in Table 2.4. The naming of the 5 KLF2 shRNAs denotes the base
position in the KLF2 mRNA. Oligonucleotides were annealed and ligated to obtain the
entire shRNA coding sequence which was then cloned into the pRRL vector using MluI
and XhoI restriction sites. Plasmids were transformed into Stbl3 E. coli (Life
Technologies) and plated on LB agar plates containing 100μg / ml Ampicillin (Thermo
Fisher Scientific). Five ampicillin resistant colonies were picked from each
transformation reaction and cultured for mini preps (Qiagen Miniprep Kit), followed by
sequencing to confirm shRNA sequence in each clone. A single colony was then used
for large scale plasmid production (Life Technologies Maxiprep Kit) for use in virus
preparation. Out of the five shRNAs tested, only two, K2sh_206 and K2sh_1529,
successfully knocked down KLF2 mRNA.
Lentiviral particles are produced by co-transfection of three plasmids into 293T cells
(semi-confluent in 10cm tissue culture dishes): packaging plasmid pCMV-dR8.74,
envelope plasmid pMD2G and the pRRL plasmid carrying our shRNA. The packaging
and envelope plasmids were a gift from Dr. Gordon Ginder’s laboratory. Transfected
293T cells are maintained at 37°C, 3% CO2 for 16-18 hours in 10ml of DMEM
containing 10% FBS and 1% P/S, after which culture medium is replaced by fresh
medium (10ml of DMEM containing 2% FBS and 1% P/S) for collection of viral particles
and 293T cells are incubated at 37°C, 10% CO2 until the medium containing viral
particles is harvested for use in infection of CD34+ cells after 32 hours. The medium
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Figure 2.2: shRNA cassette template used to design shRNAs targeting the KLF2
mRNA. The sequences of oligonucleotides for K2sh-206 (see Table 2.3) are used in
this example. Figure adapted from Ginder laboratory protocols.
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containing viral particles is first filtered through a 0.45μm filter, supplemented with
polybrene, and then 600μl of virus medium is added to 200,000 to 300,000 cells in 50μl
expansion medium. Cells are incubated at 37°C, 5% CO2. The following afternoon 650μl
of 2X expansion medium is added to the cells and the cells are returned to the incubator
for another 2 days.
2.2.4 Recovery of infected cells by FACS and differentiation into erythroid cells
On the third day after infection, infected CD34+ cells are washed 3 times with IMDM
containing 10% FBS to get rid of all viral particles, resuspended in SFEM
(approximately 10 million cells in 500μl medium), and sorted by fluorescence activated
cell sorting (FACS) using a BD FACSAriaTM II high speed cell sorter (BD Biosciences)
in the VCU Flow Cytometry Core Facility to obtain either GFP+ or RFP+ cells,
depending on which pRRL plasmid was used. Fig. 2.3 depicts sample FACS data plots
for a mock sample that has not been infected and a sample that has been infected with
an shRNA (in this case expressing RFP as the reporter gene). Cells are first gated
based on forward scatter area (FSC-A) and side scatter area (SSC-A) to select for
single cells and discard any doublets (Fig. 2.3, Gate P1). Single cells are then sorted to
retrieve cells that are positive for RFP fluorescence (Fig. 2.3,PE channel, red gate), as
an indicator that they have been infected with the desired shRNA-containing vector. The
table below the FACS plots shows the percentage of cells in each gate as a function of
the parent gate and the total number of cells. Infection efficiency ranges from 50% to
90% in our hands for all the different scramble and gene-specific constructs used.
Pelleted CD34+ cells are white in color. Sorted cells are transferred to a pro-erythroid
growth medium (see composition below) for three days, followed by erythroid
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Figure 2.3: FACS is used to retrieve cells that have been successfully transduced.
Representative FACS plots for a mock-treated sample and an shRNA-infected sample
depicting the method by which cells that have been successfully infected are selected
by FACS. Cells are first gated based on forward scatter area (FSC-A) and side scatter
area (SSC-A) to select for single cells and discard any doublets (Gate P1). Single cells
are then sorted to retrieve cells that are positive for RFP fluorescence PE channel, red
gate), as an indicator that they have been infected with the desired shRNA-containing
vector. The table below the FACS plots shows the percentage of cells in each gate as a
function of the parent gate and the total number of cells.
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differentiation medium (see composition below) for five days. On the eighth day after
sorting, erythroid cells, which are deep red in color by this day, are harvested for
interrogation. Because the cells have been exposed to erythropoietin (Epo) for 8 days,
the day of harvest is termed differentiation day 8 (DD8). In order to confirm that the
majority of cells harvested are erythroid cells, a small fraction of cells are stained with
fluorophore-conjugated antibodies that recognize surface epitopes, on erythroid cells
(see below, and as described in section 1.1.3). In addition, cytospins of cells from each
sample and treatment level are prepared to study cellular morphological details by
Wright-Giemsa staining.
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Table 2.4: Oligonucleotide sequences for construction of KLF2 shRNA vectors
KLF2 shRNA
KLF2_sh206

KLF2_sh1130

KLF2_sh1452

KLF2_sh1476

Oligo name

Oligo sequence 5’-3’

shKLF2_206.AF

CGCGTCCCCCTCAACAGCGTGCTGGACTTC
AT

shKLF2_206.AR

TCTCTTGAAATGAAGTCCAGCACGCTGTTGA
GGGGGA

shKLF2_206.BF

TTCAAGAGAATGAAGTCCAGCACGCTGTTGA
GTTTTTGGAAC

shKLF2_206.BR

TCGAGTTCCAAAAACTCAACAGCGTGCTGG
ACTTCAT

shKLF2_1130.AF

CGCGTCCCCCTGCACATGAAACGGCACATG
TA

shKLF2_1130.AR

TCTCTTGAATACATGTGCCGTTTCATGTGCA
GGGGGA

shKLF2_1130.BF

TTCAAGAGATACATGTGCCGTTTCATGTGCA
GTTTTTGGAAC

shKLF2_1130.BR

TCGAGTTCCAAAAACTGCACATGAAACGGCA
CATGTA

shKLF2_1452.AF

CGCGTCCCCGTGATGCCTTGTGAGAAAT

shKLF2_1452.AR

TCTCTTGAAATTTCTCACAAGGCATCACGGG
GA

shKLF2_1452.BF

TTCAAGAGAATTTCTCACAAGGCATCACTTTT
TGGAAC

shKLF2_1452.BR

TCGAGTTCCAAAAAGTGATGCCTTGTGAGAA
AT

shKLF2_1476.AF

CGCGTCCCCGCCTTAATTTGTACTGTCT
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KLF2_sh1529

shKLF2_1476.AR

TCTCTTGAAAGACAGTACAAATTAAGGCGGG
GA

shKLF2_1476.BF

TTCAAGAGAAGACAGTACAAATTAAGGCTTTT
TGGAAC

shKLF2_1476.BR

TCGAGTTCCAAAAAGCCTTAATTTGTACTGTC
T

shKLF2_1529.AF

CGCGTCCCCGACAAATATTGTATTACTGTACA

shKLF2_1529.AR

TCTCTTGAATGTACAGTAATACAATATTTGTCG
GGGA

shKLF2_1529.BF

TTCAAGAGATGTACAGTAATACAATATTTGTCT
TTTTGGAAC

shKLF2_1529.BR

TCGAGTTCCAAAAAGACAAATATTGTATTACT
GTACA
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2.2.5 Cell surface immunofluorescence staining for markers of erythroid
differentiation
200,000 to 1 million cells are collected in 1.5ml Eppendorf tubes, rinsed with and
resuspended in 100μl of cell staining buffer (10% FBS in PBS). To this is added 5μl
(0.06μg) of APC-conjugated anti-CD71 (Transferrin receptor) antibody and 7.5μl
(0.015μg) of PE-conjugated anti-CD235a (Glycophorin A) antibody (eBioscience). When
RFP is the reporter gene present in transduced cells, the PE-conjugated anti-CD235a
antibody is substituted with a PE-Cy7-conjugated antibody (BioLegend). The cells are
incubated with the antibodies on ice, in the dark, for 20 minutes. After staining is
complete, cells are washed with and resuspended in 300μl of cell staining buffer (10%
FBS in PBS). Distribution of CD71 and CD235a on the surface of erythroid cells is
analyzed by measuring fluorescence intensity of each epitope by flow cytometry using
the BD FACSCanto™ II Analyzer. On day 8 of differentiation most cells are at the
erythroblast stage of maturation and display a CD71HICD235aHI phenotype. These cells
are considered “double positive” for these two markers. Cells that are either
CD71HICD235LOW or CD71LOWCD235aHI are also erythroid cells, but at an earlier or later
stage of erythroid maturation respectively. Cells that are CD71LOW CD235aLOW are
considered to be non-erythroid cells.
2.2.6 RNA extraction and cDNA synthesis
1-2 million erythroid cells harvested on DD8 are processed for RNA extraction using
Trizol reagent (Life Technologies) according to the manufacturer’s protocol. The RNA
pellet obtained was resuspended in 20μl of RNase-free water (USB Corporation)
containing SuperaseIn (1:20 dilution, Ambion). 1μl of this sample was diluted 1:10 and
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used to determine RNA integrity and concentration using the Agilent Bioanalyzer and
the Agilent RNA 6000 Nano kit (Agilent Technologies), following the manufacturer’s
protocol. 1μg of RNA per sample was treated with DNaseI (Life Technologies) and used
to prepare cDNA following the instructions of the iScript cDNA synthesis kit (Biorad).
The cDNA thus obtained was diluted as required and used to determine gene
expression changes by quantitative reverse transcriptase PCR (qRT-PCR).
2.2.7 Quantitative reverse transcriptase PCR (qRT-PCR)
Changes in gene expression were measured by quantitative PCR (qPCR) using cDNA
prepared as described above. qPCR was carried out using SYBR Green or Taqman
reagent (Applied Biosystems) and plates were run on an ABI Prism 7900HT analyzer
(Applied Biosystems). The relative quantification method (E^Ctendogenous gene / E^Cttestgene,
where E = efficiency of primer set) was employed to analyze changes in gene
expression in knockdown samples compared to scramble controls. Additionally, the
expression of each gene was set to 100 for scramble-treated cells and fold change over
scramble was calculated for KLF1-shRNA or KLF2-shRNA infected cells, to minimize
variations observed due to differences between individuals. A standard curve was run
for each gene as described earlier and used to calculate the efficiency of the respective
primer set.
2.2.8 Statistical analysis
The Student’s t-test was used for statistical analyses. p values < 0.05 were considered
significant.
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Chapter 3: Krϋppel-like transcription factors KLF1 and KLF2
have unique and coordinate roles in regulating embryonic
erythroid precursor maturation

3.1 INTRODUCTION
Erythropoiesis in the mouse, and other mammals, proceeds in two distinct waves
during development (McGrath and Palis 2008). First, primitive erythroid cells appear in
the yolk sac, an extra-embryonic membrane, in regions known as blood islands
(Ferkowicz and Yoder 2005; Haar and Ackerman 1971). Large, nucleated primitive
erythroid cells begin to circulate at about mouse embryonic day 8.25 (E8.25) (Palis et al.
1999; Palis 2008). Mouse primitive erythroid progenitor cells form colonies (EryP-CFC)
in semi-solid culture media (Palis et al. 1999), which can first be detected at E7.
Primitive erythroid cells mature in circulation in a synchronous manner and eventually
undergo enucleation (Kingsley et al. 2004). The second wave, or definitive
erythropoiesis, begins in the fetal liver and results in mature, enucleated definitive
erythroid cells by around E12 (McGrath and Palis 2008).
The erythroid developmental program is regulated by a network of key
transcription factors (Baron, Vacaru, Nieves 2013), including Krüppel-like factor 1 (KLF1
or EKLF, Erythroid Krüppel-like factor). Members of the KLF family have three Cys2His2 zinc fingers near their C-terminus (McConnell and Yang 2010). KLF1 is erythroidspecific and required for the normal expression of the embryonic and adult -like globin
genes (Basu et al. 2007; Nuez et al. 1995; Perkins, Sharpe, Orkin 1995). KLF1-/- mice
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develop -thalassemia and die by E16 (Nuez et al. 1995; Perkins, Sharpe, Orkin 1995).
KLF1 regulates the expression of numerous other erythroid genes, including those
encoding cytoskeletal and membrane proteins, and heme synthesis enzymes (Hodge et
al. 2006; Pang et al. 2012). In addition, KLF1 regulates cell cycle control, proliferation
and apoptosis (Pilon et al. 2008; Tallack et al. 2009; Tallack et al. 2012). Pathogenic
mutations in KLF1 can cause congenital dyserythropoietic anemia in humans (Arnaud et
al. 2010; Jaffray et al. 2013). Interestingly, certain human mutations result in higher than
normal amounts of -globin, or hereditary persistence of fetal hemoglobin (Borg et al.
2010; Zhou et al. 2010).
To date, 17 mammalian KLFs have been identified, and they have diverse roles
in development (McConnell and Yang 2010). The zinc finger domain of KLF2 is 89%
similar to KLF1. KLF2 is necessary for primitive erythropoiesis, and positively regulates
embryonic globin gene expression, as shown in KLF2 knockout and erythroidconditional knockout mouse embryos (Alhashem et al. 2011; Basu et al. 2005; Basu et
al. 2007). There are a greater percentage of apoptotic erythroid cells in KLF2-/- than in
normal E10.5 yolk sacs (Basu et al. 2005). Global gene expression assays indicate that
many genes important in the processes of development, differentiation and cell
migration are dysregulated in KLF2-/- compared to wild-type primitive erythroid cells
(Redmond et al. 2011). Ablation of KLF2 causes lethality between E11.5 and E14.5
(Chiplunkar et al. 2013; Wani, Means, Lingrel 1998), due to severe intra-embryonic
hemorrhaging (Kuo et al. 1997) and/or heart failure (Lee et al. 2006).
KLF1 and KLF2 share functional roles in globin gene regulation. KLF1 and KLF2
can partially compensate for each other, as is evident from the reduced embryonic β-
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like globin gene expression of KLF1/KLF2 double (KLF1-/-KLF2-/-) compared to single
knockout embryos (Basu et al. 2007). There is also more aberrant morphology,
consistent with increased apoptosis, in double compared to single knockout primitive
red blood cells. In addition, E10.5 KLF1-/-KLF2-/- embryos are strikingly pale and
appear anemic, whereas E10.5 KLF1-/- and E10.5 KLF2-/- mice are grossly normal. In
addition, KLF1-/-KLF2-/- mice die by E11.5, which is earlier than KLF1-/- or KLF2-/embryos. Gene expression profiling of E9.5 erythroid cells was used to identify genes
that are synergistically regulated by KLF1 and KLF2 (Pang et al. 2012). These genes
are principally involved in cellular pathways that control homeostasis, hemopoiesis,
apoptosis and proliferation. Erythroid conditional knockout and other functional studies
identified Myc as an important downstream target of KLF1 and KLF2. Additional
potential targets include other genes governing proliferation and/or apoptosis, such as
Cd24a antigen (Nielsen et al. 1997), forkhead box M1 (FoxM1) (Wierstra and Alves
2007), sphingosine kinase 1 (Sphk1) (Le Scolan et al. 2005) and parathyroid hormone 1
receptor (Pthr) (Qian et al. 2003).
In this work, we further assess how KLF1 and KLF2 coordinately control primitive
erythropoiesis. Our first aim was to determine whether an erythroid cell-autonomous
function of KLF2 is responsible for the development of anemia in KLF1-/-KLF2-/- E10.5
mouse embryos. We were also interested in determining the cause of the anemia,
through identification of cellular processes and molecular regulators that are
dysregulated in the absence of KLF1 and KLF2. We demonstrate that E10.5 KLF1/KLF2
double erythroid-conditional knockout embryos are anemic like KLF1-/-KLF2-/- mice. A
surprising new discovery was made, in that restoring one copy of the KLF2 (KLF1-/-
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KLF2+/-) but not the KLF1 gene (KLF1+/-KLF2-/-) ameliorates this phenotype. Anemia
in E10.5 KLF1+/-KLF2-/- and KLF1-/-KLF2-/- mice correlates with a drastic reduction in
the number of peripheral blood cells. EryP-CFC assays identified a novel role for KLF2
in the maintenance of primitive erythroid progenitor potential. KLF1 can partially
compensate for KLF2 in this function, but its pivotal role is in the regulation of cell
proliferation. KLF1-/-KLF2-/- embryos have more severely impaired colony forming
ability than single knockouts. The data indicate that KLF1 and KLF2 coordinately control
the maturation of primitive erythroid precursors.
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3.2 RESULTS
3.2.1 KLF1/KLF2 double conditional KO embryos recapitulate the KLF1-/-KLF2-/anemia phenotype
KLF1 has an erythroid specific pattern of expression. However, KLF2 has a
broader tissue distribution, with expression observed in erythroid and endothelial cells,
T-cells and lung tissue. We wished to determine whether the anemia phenotype
observed in E10.5 KLF1-/-KLF2-/- mouse embryos is a result of the erythroid cellautonomous functions of KLF2. In order to determine whether the anemia observed in
KLF1-/-KLF2-/- embryos results from erythroid cell-specific ablation of KLF2, the ideal
mouse model would be an erythroid conditional knockout of KLF2 on a KLF1 null
background. Unfortunately, ErGFP-Cre expression (Alhashem et al. 2011; Heinrich,
Pelanda, Klingmuller 2004) is dependent on KLF1 (Fig. 3.1). Consequently, there was
no reduction in the amount of KLF2 mRNA in KLF1-/-KLF2F/F,ErGFP-Cre blood cells
(data not shown), and this model was untenable. The -Cre transgenic model (Peterson
et al. 2004) was also unworkable because the KLF1 and -Cre genes are apparently
linked. In Tie2-Cre mice, Cre is expressed in erythroid cells as early as E7.5 (Tang et al.
2010). Therefore this model was used for conditional deletion of KLF2 on a KLF1 null
background, with the caveat that KLF2 is ablated in erythroid and endothelial cells.
KLF1+/-KLF2F/+,Tie2-Cre and KLF1+/-KLF2F/F mice were mated to obtain
E10.5 embryos of the following genotypes: KLF1-/-KLF2F/F,Tie2-Cre (KLF1/KLF2
double conditional KO or dcKO), KLF1-/-KLF2F/F (KLF1 KO) and KLF1+/+KLF2F/+
(wild-type control). At E10.5, wild-type (Fig. 3.2A), KLF1 KO (Fig. 3.2B) and
KLF2F/F,Tie2-Cre (KLF2 conditional KO, Fig. 3.2C) embryos are surrounded by yolk
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Figure 3.1. ErGFP-Cre mRNA expression is regulated by KLF1 in erythroid cells.
ErGFP-Cre mRNA expression in KLF2F/F,ErGFP-Cre (n=3) E10.5 peripheral blood
compared to KLF1-/-KLF2F/F,ErGFP-Cre (n=5). The ErGFP-Cre-to-Cyclophilin A mRNA
ratio for KLF2F/F,ErGFP-Cre was taken as 100%. Cyclophilin A mRNA was used as an
internal standard for qRT-PCR. Error bars indicate standard deviation. * p < 0.025
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Figure 3.2: KLF1/KLF2 double conditional KO embryos recapitulate the KLF1-/KLF2-/- anemia phenotype. E10.5 whole-mount embryos surrounded by yolk sacs. (A)
Wild-type embryos (KLF1+/+KLF2F/+, n=3) have distinct red blood vessels. (B) KLF1
KO (KLF1-/-KLF2F/F, n=4) and (C) KLF2 conditional KO (KLF2F/F,Tie2-Cre, n=1)
embryos are similar in appearance to wild-type embryos. (D) KLF1/KLF2 double
conditional KO embryos (KLF1-/-KLF2F/F,Tie2-Cre, n=4) appear anemic in contrast to
A, B and C. (E) KLF1-/-KLF2F/+,Tie2-Cre embryos with one normal KLF2 gene appear
grossly normal (n=2); whereas (F) a KLF1+/-KLF2F/F, Tie2-Cre (n=1) embryo, with one
functional KLF1 gene, appears anemic. Photographs were taken at 15 magnification.
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sacs with distinctly red blood vessels. In comparison, E10.5 KLF1/KLF2 dcKO mice
(Fig. 3.2D) are pale and appear anemic, similar to KLF1-/-KLF2-/- embryos (Basu et al.
2007).
In the course of these experiments, a few recombinant embryos of the genotypes
KLF1-/-KLF2F/+,Tie2-Cre and KLF1+/-KLF2F/F,Tie2-Cre were obtained. An interesting
and surprising observation was that E10.5 KLF1-/-KLF2F/+,Tie2-Cre embryos (Fig.
3.2E), having one KLF2 allele, have yolk sacs with visibly red blood vessels similar to
wild-type (Fig. 3.2A), but a KLF1+/-KLF2F/F,Tie2-Cre embryo (Fig. 3.2F), with one
KLF1 allele, appears anemic like KLF1/KLF2 dcKO embryos (Fig. 3.2D). In order to
verify this observation, matings were performed to obtain several E10.5 KLF1-/-KLF2+/and KLF1+/-KLF2-/- embryos. KLF1-/-KLF2+/- embryos are similar to wild-type embryos
with distinct red blood vessels (Fig. 3.3A), while KLF1+/-KLF2-/- embryos appear
anemic (Fig. 3.3B). Thus, the complete knockout embryos have gross phenotypes
similar to the conditional knockout mice. These findings confirm that one functional
KLF2 gene, but not one KLF1 allele, can ameliorate the anemia phenotype.
To determine whether the pale appearance of KLF1/KLF2 dcKO embryos is due
to a defect in the development of blood vessels, yolk sac tissue sections from 3
embryos of each genotype were studied. Blood islands consisting of blood cells (Ery)
surrounded by endothelial cells (En) are situated between the epithelium (Ep) and
mesothelium (Me), as shown for wild-type in Figs. 3.4A and 3.4D.

The yolk sac

vasculature of KLF2 KO (Basu et al. 2005), KLF1 KO (Figs. 3.4B and 3.4E) and
KLF1/KLF2 dcKO embryos (Figs. 3.4C and 3.4F) appears normal, with well-defined
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blood vessels lined by endothelial cells. This suggests that aberrant erythroid rather
than vascular development causes the anemia phenotype.
Because the yolk sac vasculature of KLF1/KLF2 dcKO mouse embryos appears
normal, the globin mRNA amount in the erythroid cells was queried. E10.5 peripheral
blood cells were collected from wild-type, KLF1-/- and KLF1/KLF2 dcKO embryos. RNA
prepared from these cells was used to quantify βh1- and Ey-globin expression by qRTPCR. In addition to these three genotypes, previous data for E10.5 KLF2F/F,ErGFP-Cre
(KLF2 erythroid conditional knockout or KLF2Ery-cKO) embryos is included (Alhashem
et al. 2011; Heinrich, Pelanda, Klingmuller 2004). A direct comparison can be drawn
between KLF1/KLF2 dcKO and KLF2 Ery-cKO embryos because there is a similar
amount of KLF2 mRNA remaining in the embryonic erythroid cells of each genotype
((Alhashem et al. 2011) and unpublished data).
Compared to wild-type embryos, KLF2 Ery-cKO and KLF1-/- embryos have an
approximately 20% and 35% reduction in βh1-globin mRNA, respectively (Fig. 3.5A,
p<0.001).The amount of βh1-globin mRNA in KLF1/KLF2 dcKOs is reduced to less than
50% of that in wild-type embryos, significantly lower than eitherKLF2 Ery-cKO or KLF1/- (Fig. 3.5A, p<0.025). A similar decreasing trend is observed in the amount of Eyglobin mRNA (Fig. 3.5B). The amount of Ey-globin mRNA in KLF1/KLF2 dcKOs is
reduced to approximately 50% of that in wild-type embryos (p<0.001). Although these
decreases are significant, they are not great enough to explain the observed anemia
phenotype in KLF1/KLF2 dcKO embryos.
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Figure 3.3: Gene dosage of KLF1 and KLF2 impacts the anemia phenotype. E10.5
whole-mount embryos surrounded by yolk sacs. (A) Embryos with one normal KLF2
gene, (A) KLF1-/-KLF2+/- (n=3) appear grossly normal; whereas (B) KLF1+/-KLF2-/(n=3) embryos, with one functional KLF1 gene, appear anemic. Photographs were
taken at 15 magnification.
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Figure 3.4: KLF1/KLF2 double conditional KO embryos have normal yolk sac
blood vessels. Blood islands from wild-type (A and D), KLF1 KO (B and E) and
KLF1/KLF2 double conditional KO (C and F) yolk sacs. n=3 for each genotype. A,B and
C are 400; and D, E and F are 1000 magnification. The abbreviations used are
columnar epithelium (Ep), blood cells (Ery) and endothelial/mesothelial layer (En + Me
L).

73

Figure 3.5. KLF1/KLF2 double conditional KO erythroid cells have reduced
embryonic βh1- and Ey-globin mRNA. Mouse embryonic (A) βh1-globin and (B) Eyglobin mRNA expression in E10.5 erythroid cells from wild-type (WT), KLF2F/F,ErGFPCre; KLF1-/-KLF2F/F and KLF1-/-KLF2F/F,Tie2-Cre. KLF2F/F,ErGFP-Cre, KLF1-/KLF2F/F and KLF1-/-KLF2F/F,Tie2-Cre blood cells have less βh1-globin mRNA than
wild-type (p<0.001). KLF1-/-KLF2F/F and KLF1-/-KLF2F/F,Tie2-Cre blood cells have
less Ey-globin mRNA than wild-type (p<0.001). Cyclophilin A mRNA was used as an
internal standard for qRT-PCR. The globin-to-cyclophilin A mRNA ratio for WT was
taken as 100%. n=6-8 for each genotype. Error bars indicate standard deviation.
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3.2.2 E10.5 KLF1+/-KLF2-/- and KLF1-/-KLF2-/- embryos have fewer peripheral
blood cells than KLF1-/-KLF2+/We had previously shown that E10.5 KLF1-/-KLF2-/- embryos have fewer
peripheral blood cells than wild-type (Pang et al. 2012). In order to understand the
contributions of KLF1 and KLF2 to the starkly different erythropoietic phenotypes of
E10.5 KLF1+/-KLF2-/- and KLF1-/-KLF2+/- embryos, the number of circulating blood
cells in these embryos was determined. KLF1-/-KLF2+/-, KLF1+/-KLF2-/- and KLF1-/KLF2-/- embryos have fewer peripheral blood cells than wild-type (Fig. 3.6A, p<0.005).
Of particular interest was the observation that KLF1+/-KLF2-/- have significantly fewer
peripheral blood cells than KLF1-/-KLF2+/- embryos (Fig. 3.6A, p<0.01). The number of
blood cells in the anemic KLF1+/-KLF2-/- and KLF1-/-KLF2-/- embryos is similar, and is
several-fold less than wild-type. KLF1-/-KLF2+/- embryos have an intermediate number
of blood cells, between these two classes.
The amount of embryonic βh1- and Ey-globin mRNA in peripheral blood cells
from these embryos was determined using qRT-PCR. E10.5 peripheral blood cells were
collected from wild-type, KLF1-/-KLF2+/-, KLF1+/-KLF2-/- and KLF1-/-KLF2-/- embryos.
KLF1-/-KLF2+/-, KLF1+/-KLF2-/- and KLF1-/-KLF2-/- blood cells all have an
approximately 50% reduction in the amount of βh1-globin (Fig. 3.6B) and Ey-globin
mRNA (Fig. 3.6C) compared to wild-type. There are no significant differences in the
amounts of βh1- and Ey-globin mRNA between these 3 mutant genotypes. Therefore,
disparities in globin gene expression do not explain the difference between the
phenotypes of KLF1+/-KLF2-/- and KLF1-/-KLF2+/- embryos with regard to anemia. The
measurements of the amount of globin mRNA per cell and the number of blood cells per
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Figure 3.6. E10.5 KLF1+/-KLF2-/- and KLF1-/-KLF2-/- embryos have fewer
peripheral blood cells than KLF1-/-KLF2+/- embryos. (A) KLF1-/-KLF2+/-, KLF1+/KLF2-/- and KLF1-/-KLF2-/- embryos have fewer peripheral blood cells than wild-type
(WT) embryos (* = p<0.005). Other significant p-values are as shown by brackets.
KLF1+/-KLF2-/- and KLF1-/-KLF2-/- embryos have fewer peripheral blood cells than
KLF1-/-KLF2+/-, correlating with the anemia phenotype. The amount of mouse
embryonic (B) βh1-globin and (C) Ey-globin mRNA is reduced in KLF1-/-KLF2+/-,
KLF1+/-KLF2-/- and KLF1-/-KLF2-/- blood cells compared to wild-type (WT) (* =
p<0.05). Gapdh mRNA was used as an internal standard for qRT-PCR. The globin-toGapdh mRNA ratio for WT was taken as 100%. n=4-10 for each genotype. Error bars
indicate standard deviation.
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embryo were multiplied to calculate the total embryonic globin per embryo. KLF1-/KLF2+/- embryos have approximately 4-fold less, whereas KLF1+/-KLF2-/- and KLF1-/KLF2-/- embryos have approximately 10-fold less total globin per embryo than wild-type.
Based on these findings, we conclude that a combined reduction in globin per cell and
in number of peripheral blood cells contributes to the anemic phenotype of E10.5
KLF1+/-KLF2-/- and KLF1-/-KLF2-/- embryos.
E10.5 KLF1-/-KLF2+/- embryos may escape anemia because a compensatory
increase in KLF2 mRNA expression ameliorates the phenotype. To test this hypothesis,
the amount of KLF2 mRNA in blood cells of E10.5 wild-type and KLF1-/- embryos was
quantified by qRT-PCR. An approximately 2.5 fold increase in KLF2 mRNA amount was
observed in KLF1-/- blood cells compared to wild-type (Fig. 3.7), supporting this
postulate.

3.2.3 KLF1-/- and KLF1-/-KLF2-/- erythroblasts display impaired G1- to S-phase
cell cycle progression
There is prior evidence that primitive and definitive KLF1-/- blood cells show cell
cycle defects (Pilon et al. 2008; Tallack et al. 2009). Furthermore, KLF1 directly
regulates E2f2 and p18, genes that control cell cycle progression (Pilon et al. 2008;
Tallack, Keys, Perkins 2007; Tallack et al. 2009). To determine whether KLF1 and KLF2
have overlapping functions in cell cycle regulation, and whether changes in proliferation
are responsible for the observed reduction in KLF1-/-KLF2-/- blood cells, the cell cycle
profiles of E9.5 erythroblasts from these embryos were compared to KLF1-/-, KLF2-/and wild-type littermates. After culturing the cells for 90 minutes in medium containing
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Figure 3.7. Compensatory increase in KLF2 mRNA in KLF1-/- blood cells. KLF2
mRNA expression in KLF1 KO (KLF1-/-KLF2F/F, n=9) E10.5 peripheral blood compared
to wild type (n=4). The KLF2-to-cyclophilin mRNA ratio for wild type was taken as 100%.
Cyclophilin A mRNA was used as an internal standard for qRT-PCR. Error bars indicate
standard deviation. * p < 0.025
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BrdU, an average of 18.8% of wild-type erythroblasts are in G0/G1, 79.7% are in Sphase and 1.5% are in G2/M (Fig. 3.8). It was somewhat surprising that such a high
percentage of normal E9.5 cells are in S-phase. However, Malik et al. reported similar
results for E10.5 erythroblasts (Malik et al. 2013). The cell cycle distribution of KLF2-/erythroblasts is similar to wild-type, suggesting that KLF2 ablation alone does not affect
cell cycle progression. KLF1-/- and KLF1-/-KLF2-/- embryos have an approximately
20% reduction in the number of cells in S-phase, compared to wild-type. This is
accompanied by an approximately 2-fold increase in the percentage of cells in the
G0/G1 phase of the cell cycle, suggesting a block in S-phase entry. There were no
significant differences between the cell cycle profiles of KLF1-/- and KLF1-/-KLF2-/erythroblasts. The data suggest that KLF1 has a unique role in regulating cell cycle
progression in E9.5 erythroblasts that is not shared by KLF2. Simultaneous ablation of
KLF2 does not exacerbate the cell cycle disruption in KLF1-/- red blood cells. This work
with E9.5 KLF1-/- erythroblasts extends and confirms other reports of cell cycle defects
in KLF1-/- blood cells (Pilon et al. 2008; Tallack et al. 2009).

3.2.4 KLF1-/-KLF2-/- embryos have defects in primitive erythroid precursor
maturation
The paucity of peripheral blood cells in KLF1-/-KLF2-/- embryos may result from
a decrease in the number or a defect in the differentiation of erythroid progenitors. To
determine whether KLF1 and KLF2 control the primitive erythroid progenitor (EryP-CFC)
compartment, we performed colony forming assays on E8.25 - E8.5 wild-type, KLF1-/-,
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Figure 3.8. KLF1-/- and KLF1-/-KLF2-/- blood cells show aberrations in G1- to Sphase progression during cell division. (A) Representative flow cytometry plots
measuring DNA content (7-AAD) and BrdU incorporation (APC-BrdU) are shown for WT
and KLF1-/-KLF2-/- embryos. The graph below depicts analyses of the percentage of
cells in G0/G1, S and G2/M phases of the cell cycle in wild-type (WT), KLF2-/-, KLF1-/and KLF1-/-KLF2-/- E9.5 erythroblasts. n = 3-9 for each genotype. Error bars indicate
standard error. * = p-value <0.01 compared to wild-type. This set of experiments was
done with assistance from Kristen Wade.
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KLF2-/- and KLF1-/-KLF2-/- embryos (Fig. 3.9A). At this stage of development, EryPCFC colony numbers reflect the number of erythroid progenitors present in the yolk sac.
On day 4 of culture, visibly red primitive erythroid colonies are observed in wild-type
(n=10) cultures (Fig. 3.9A); however, no red colonies are visible in KLF1-/-KLF2-/- (n=4)
cultures, indicating a defect in the erythroid compartment.
To further assess this defect, colonies in methylcellulose were stained with
benzidine for hemoglobin, and observed on day 6 of culture. KLF1-/- embryos gave rise
to normal numbers of EryP-CFCs (Fig. 3.9B), but the colonies are approximately 10-fold
smaller than wild-type (Fig. 3.9C). Interestingly, KLF2-/- embryos produce significantly
fewer EryP-CFCs than wild-type at day 6 (Fig. 3.9B, p<0.016), but colony size is not
distinguishable from wild-type (Fig. 3.9C). The number of EryP-CFCs derived from
KLF1-/-KLF2-/- embryos is significantly less than wild-type (Fig. 3.9B, p<0.001), KLF2-/(p<0.028) and KLF1-/- (p<0.02). The KLF1-/-KLF2-/- colonies are also smaller than wildtype, although similar in size to KLF1-/-. It was of interest to distinguish whether there
are fewer than normal progenitors in KLF1-/-KLF2-/- embryos, or if they are unable to
produce colonies that survive to day 6 of culture. Therefore the method of Malik et al.
was used to count nascent colonies on day 2 of culture (Malik et al. 2013). There are
similar numbers of EryP-CFC in KLF1-/-KLF2-/- (n=3) and KLF1+/-KLF2+/- (n=3) on day
2 (Fig. 3.9D). This suggests that normal numbers of primitive erythroid progenitors are
specified in KLF1-/-KLF2-/- embryos, but the simultaneous ablation of KLF1 and KLF2
leads to a stochastic defect in maturation of erythroid precursors, such that fewer
colonies are observed on day 6 of culture. The KLF1 and KLF2 genes interact to
synergistically control colony number. Thus aberrant precursor potential and
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Figure 3.9. KLF1-/-KLF2-/- embryos have defects in primitive erythroid precursor
maturation. E8.25 - E8.5 implants were dissociated into single cells using trypsin and
plated in methylcellulose supplemented with growth factors. Erythroid colonies were
stained with benzidine and counted on day 2 or day 6 of culture. (A) Schematic diagram
of experimental procedure (not drawn to scale). (B) Comparison of number of EryP-CFC
colonies formed per 104 cells plated from wild-type (WT), KLF2-/-, KLF1-/- and KLF1-/KLF2-/- implants on day 6 of culture. The average of number of colonies formed per 10 4
cells plated from wild type implants was set to 100% for each litter. ‘n’ indicates number
of embryos. (C) The average colony size was determined by measuring the twodimensional area of colonies from captured images. Average colony size of KLF2-/-,
KLF1-/- and KLF1-/-KLF2-/- colonies was compared to size of wild-type colonies, and
significant differences and p-values are shown by brackets. ‘n’ indicates number of
colonies analyzed from 2 to 6 embryos of each genotype. Representative colonies from
each genotype are shown below the respective genotype (100 magnification, scale
bar is 50μm). (D) Comparison of number of EryP-CFC colonies formed per 104 cells
plated from KLF1+/-KLF2+/- and KLF1-/-KLF2-/- implants on day 2 of culture. The
average of number of colonies formed per 104 cells plated from KLF1+/-KLF2+/implants was set to 100. ‘n’ indicates number of embryos. Error bars indicate standard
deviation.
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proliferation capacity likely contribute to the reduction in the number of circulating blood
cells in E10.5 KLF1-/-KLF2-/-embryos.
3.2.5 KLF1 and KLF2 modulate the expression of genes controlling proliferation
Microarray analyses had been performed to demonstrate that the expression of
five proliferation-associated genes, Foxm1, Cd24a, Myc, Sphk1 and Pthr, is
progressively reduced in wild-type, KLF1-/- and KLF1-/-KLF2-/- E10.5 blood cells (Pang
et al. 2012). Therefore, qRT-PCR was used to assess expression of these genes in
wild-type, KLF1-/-KLF2+/-, KLF1+/-KLF2-/- and KLF1-/-KLF2-/- E10.5 blood cells. The
amounts of all five mRNAs are significantly reduced in KLF1-/-KLF2+/-, KLF1+/-KLF2-/and KLF1-/-KLF2-/- blood cells compared to wild-type, verifying the microarray
analyses. Foxm1 mRNA is the only mRNA that is significantly reduced in KLF1+/-KLF2/- and KLF1-/-KLF2-/- compared to KLF1-/-KLF2+/- (Fig. 3.10A), specifically correlating
with the anemia phenotype and reduced peripheral blood cell number. Sphk1 mRNA
amounts are significantly lower in KLF1-/-KLF2-/- than in KLF1-/-KLF2+/-, but not in
KLF1+/-KLF2-/- compared to KLF1-/-KLF2+/- (Fig. 3.10B). Myc mRNA amounts are not
significantly different between KLF1-/-KLF2+/-, KLF1+/-KLF2-/- and KLF1-/-KLF2-/- (Fig.
3.10C). Cd24a and Pthr mRNA amounts are reduced in KLF1-/-KLF2+/- compared to
KLF1+/-KLF2-/-, negatively correlating with anemia phenotype (Fig. 3.10D and E). Thus,
reduced expression of all 5 genes may contribute to the decreased number of erythroid
cells in KLF1-/-KLF2+/-, KLF1+/-KLF2-/- and KLF1-/-KLF2-/- embryos compared to wildtype. However, FoxM1 is the only gene that correlates with the E10.5 anemia
phenotype, having lower expression in KLF1+/-KLF2-/- than in KLF1-/-KLF2-/- blood
cells.
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Figure 3.10. KLF1 and KLF2 modulate the expression of genes involved in
proliferation. qRT-PCR was used to determine the amount of (A) Foxm1, (B) Sphk1,
(C) cMyc mRNA, (D) Cd24a and (B) Pthr mRNA in wild-type (WT), KLF1-/-KLF2+/-,
KLF1+/-KLF2-/- and KLF1-/-KLF2-/- E10.5 blood cells. Gapdh mRNA was used as an
internal standard. Wild-type was taken as 100%. n= 4-10 per genotype. All of the
genotypes (KLF1-/-KLF2+/-, KLF1+/-KLF2-/- and KLF1-/-KLF2-/-) were significantly
different from the wild-type (* = p< 0.0001). Other significant p-values are as shown by
brackets. Error bars indicate standard deviation. This work was done with assistance
from Safa Mohamad.
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3.3 DISCUSSION
The KLF1 and KLF2 genes interact to control globin gene regulation and
primitive erythroid precursor maturation. Interactions between related transcription
factor genes in erythroid cells have previously been reported. There are normal
numbers of primitive erythroid cells in Gata1 null E9.5 yolk sac blood islands, although
these cells are less differentiated than wild-type (Fujiwara et al. 1996). E9.5 Gata2
knockout embryos have fewer erythroid cells than wild-type (Tsai et al. 1994).
Gata1/Gata2 double knockout embryos show a more severe defect in primitive
erythropoiesis than either Gata1 or Gata2 knockout embryos, with yolk sac blood
islands almost completely devoid of erythroid cells (Fujiwara et al. 2004). Functional
overlap has recently been described for KLF3 and KLF8, which act as transcriptional
repressors. KLF3 knockout mice are viable with a mild erythroid phenotype (Funnell et
al. 2012; Sue et al. 2008). KLF8 knockout mice are viable with normal erythroid
parameters (Funnell et al. 2013). The KLF3/KLF8 double knockout causes embryonic
lethality, and greater dysregulation of fetal liver gene expression than either single
knockout (Funnell et al. 2013).
We have demonstrated that the reduced number of E10.5 KLF1-/-KLF2-/peripheral blood cells stems from a defect in erythroid precursor maintenance and
maturation. Primitive erythroid progenitor colonies (EryP-CFC) derived from E8.5 KLF1/- embryos are similar in frequency but significantly smaller in size than wild-type.
Previous studies of definitive fetal liver erythroid progenitors produced somewhat
variable results with respect to the frequency of BFU-E and CFU-E colony forming units.
Perkins et al. found a similar number of BFU-E and CFU-E in E15 KLF1-/- and wild-type

85

mice (Perkins, Sharpe, Orkin 1995). Pilon et al. used sorted erythroid progenitors
(CD71LO, Ter119NEG) from E13.5 KLF1-/- fetal livers, and also found wild-type
frequencies of BFU-E (Pilon et al. 2008). However, Pilon et al. observed an increased
frequency of CFU-E in KLF1-/- compared to wild-type embryos, which was attributed to
a block in erythropoiesis. Interestingly, they observed that KLF1-/- fetal livers have
significantly fewer cells than wild-type (Pilon et al. 2008). In addition, BFU-E and CFU-E
colonies from KLF1-/- embryos contain less hemoglobin and require 28-48 hours longer
to reach the same size as wild-type BFU-E and CFU-E, suggesting a defect in
proliferation, analogous to our findings for embryonic progenitors (16). This suggests
that KLF1, though present in a lower amount in primitive than in definitive erythroid cells
(Alhashem et al. 2011; Zhou et al. 2006), plays a similar role in proliferation at both
stages.
A novel role for KLF2 in the maintenance of mouse primitive erythroid precursors
has been identified in this work. This correlates with ENCODE data from the Ross
Hardison laboratory, which indicates that KLF2 is robustly expressed in mouse adult
megakaryocyte-erythroid progenitors (MEPs) (UCSC Accession: wgEncodeEM003184).
Investigations into the role of KLF2 in definitive erythroid progenitors have produced
discordant results. Wani et al. reported a severe reduction in the number of CFU-E
derived from E11.5 KLF2-/- fetal liver progenitors compared to wild-type (Wani, Means,
Lingrel 1998). However, Kuo et al. found normal numbers of erythroid colonies in KLF2/- fetal liver cultures (Kuo et al. 1997). Our studies reveal that KLF2-/- embryos have
fewer primitive erythroid progenitor colonies than wild-type embryos on day 6 of culture.
KLF1 can partially compensate for the lack of KLF2, because fewer EryP-CFC are
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obtained from KLF1-/-KLF2-/- than from KLF2-/- embryos. Interestingly, there are
normal numbers of erythroid colonies derived from KLF1-/-KLF2-/- embryos on day 2 of
culture. A model consistent with these observations is that only some KLF1-/-KLF2-/colonies are maintained beyond day 2, due to a stochastic selection event. It has been
established that KLF2 ablation leads to increased apoptosis in E10.5 yolk sac erythroid
cells (Basu et al. 2005), and there is some evidence of a modest increase in apoptosis
in KLF1-/- definitive erythroid cells (Tallack et al. 2012). Although it is not possible to
study apoptosis directly in E8.5 erythroid progenitor cells in this model system, the
stochastic event in KLF1-/-KLF2-/- cultures might logically involve apoptosis.
The importance of KLF1 and KLF2 gene dosage for the regulation of several
proliferation genes has been demonstrated. The transcription factor FoxM1 stimulates
proliferation by promoting S-phase and M-phase entry in the cell cycle (Wierstra 2013).
FoxM1-/- embryos have approximately 3-fold fewer cardiomyocytes, with defects in
DNA replication and mitosis (Ramakrishna et al. 2007), but no increase in apoptosis
was noted in these cells or in other FoxM1-/- mouse models (Ramakrishna et al. 2007;
Wierstra and Alves 2007). FoxM1 mRNA is present in lower amounts in KLF1+/-KLF2-/than in KLF1-/-KLF2+/- embryonic erythroid cells, suggesting that it is more responsive
to KLF2 than KLF1, and correlating with the anemia phenotype in E10.5 KLF1+/-KLF2-/but not KLF1-/-KLF2+/- embryos.

Although the difference in FoxM1 expression

between KLF1-/-KLF2+/- and KLF1+/-KLF2-/- embryos is modest, we speculate that
small changes could have large effects in a milieu where the expression of multiple
proliferation genes is dysregulated. A requirement for KLF2 in the regulation of a set of
genes, including Foxm1, may contribute to the reduced number of circulating blood cells
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in KLF1+/-KLF2-/- compared to KLF1-/-KLF2+/- embryos. In addition, there is a modest
increase in KLF2 mRNA in KLF1-/- blood cells, possibly contributing to the KLF1-/KLF2+/- phenotype.
In summary, the Krϋppel-like transcription factors KLF1 and KLF2 are critical for
embryonic erythropoiesis. They are expressed at similar amounts and display functional
compensation in primitive erythroid cells. This is evident in the dramatic anemia
phenotype observed in KLF1/KLF2 double knockout but not in KLF1 or KLF2 single
knockout embryos at E10.5. In this study, we show that the anemia is primarily due to a
reduction in the number of peripheral blood cells. Surprisingly, the anemia and the
number of erythroid cells observed in E10.5 embryos is dose dependent, with more
peripheral blood cells in KLF1-/-KLF2+/- than in KLF1+/-KLF2-/- embryos. KLF1 and
KLF2 have a greater than additive positive effect on maintaining the colony forming
ability of E8.5 erythroid progenitor cells, but KLF2 depletion alone leads to a reduced
number of colonies compared to wild-type. These data suggest that certain genes
involved in the maturation or proliferation of red blood cells are preferentially responsive
to regulation by KLF2, as opposed to KLF1. Further studies of the roles of KLF1 and
KLF2 in erythroid precursor maturation may lead to novel therapeutic strategies for the
anemias.
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Chapter 4: Control of -like globin gene expression in an in vitro
model of human fetal erythropoiesis
4.1 INTRODUCTION
Hemoglobinopathies are a group of genetic disorders that affect millions of
people worldwide (Weatherall 2006). They are caused by abnormalities in the structure
or amount of hemoglobin produced in red blood cells. Hemoglobin, the protein
responsible for transport of oxygen from the lungs to the various tissues of the body, is
a tetramer composed of two -globin chains and two -globin chains, each of which is
tightly linked to an iron-containing heme group. Sickle cell anemia and -thalassemia
are two of the most common hemoglobinopathies, and they result from defects in the
structure and amount of -globin chains, respectively. The year 2010 marked a century
since the initial description of sickle cell disease (Herrick 2001). This period has been an
era of intense research aimed at elucidating the molecular pathophysiology of sickle cell
disease and other hemoglobinopathies (Orkin and Higgs 2010; Sankaran and Nathan
2010). The advent of molecular biology in particular has greatly advanced our
understanding of disease mechanisms. However, affected patients still lack a widely
applicable and easily available cure. It is hoped that by 2025, the year that marks the
centenary of the initial reports of thalassemia, new therapies for the hemoglobinopathies
will be on the horizon.
The human -globin locus is situated on chromosome 11 and consists of 5 -like
globin genes: ε, G, A,  and -globin. These genes are developmentally regulated and
expressed in the order in which they are present on the chromosome. Thus ε-globin is
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expressed during early embryonic development in yolk sac-derived primitive erythroid
cells, -globin during the fetal period in fetal liver-derived definitive erythroid cells and (<2%) and -globin (~98%) during adult life in bone-marrow derived definitive erythroid
cells. This sequential change in -like globin gene expression is termed “hemoglobin
switching”. In the majority of people, fetal -globin expression is silenced after birth to
barely detectable levels (<2%). However in some people -globin continues to be
expressed throughout the person’s lifetime. The level of -globin expressed varies
greatly from case to case. This phenomenon is known as hereditary persistence of fetal
hemoglobin (HPFH) and is clinically asymptomatic (Forget 1998). It was observed that
patients with sickle cell anemia or -thalassemia who also have HPFH manifest less
severe disease symptoms, suggesting that -globin can substitute for -globin in adult
erythrocytes (Weatherall 2001). This discovery prompted researchers to study the
molecules and mechanisms that control hemoglobin switching, with the aim of reexpressing -globin in patients with -hemoglobinopathies. In order to achieve this goal,
it is imperative that we gain a better understanding of two important aspects of -globin
gene regulation: (1) activation of gene expression or the mechanisms by which the globin gene is turned on in the fetus and (2) repression of gene expression or the
mechanisms by which the -globin gene is silenced in adults. A composite approach
that encompasses both these complimentary regulatory mechanisms will likely produce
the most effective therapeutic strategy.
Recent studies have implicated Krüppel-like factor 1 (KLF1), a member of the
Krüppel-like factor family of Cys2-His2 zinc finger transcription factors, as having a
substantial role in the - to -globin switch (Borg et al. 2010; Zhou et al. 2010). Borg et
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al determined through linkage analysis that a heterozygous nonsense mutation in KLF1
was responsible for HPFH in members of a Maltese family (Borg et al. 2010).
Knockdown of KLF1 in erythroid cells derived from adult CD34+ hematopoietic
progenitors resulted in increased expression of -globin (Borg et al. 2010; Zhou et al.
2010). It has been proposed that this negative regulation of -globin by KLF1 is an
indirect effect through Bcl11a, a repressor of -globin, which shows decreased
expression in this system (Borg et al. 2010; Zhou et al. 2010). KLF1 regulation of
Bcl11a may be direct since KLF1 binds to the Bcl11a promoter (Sankaran et al. 2008).
In contrast to these results, studies using compound KLF1-/- / -YAC transgenic
mice have shown that there is decreased expression of -globin in yolk sacs of E10.5
embryos (Alhashem et al. 2011). Furthermore, KLF1 binds to the -globin promoter in
primitive erythroid cells from wild-type -YAC transgenic mice. Of particular interest was
the observation that KLF2 also binds to the -globin promoter in these cells and
compound KLF2-/- / -YAC transgenic mice show a modest decrease in -globin
expression (Alhashem et al. 2011). While the mouse is an invaluable model system in
many respects, one drawback of studying human globin gene regulation in a mouse
model is that -globin is expressed in the fetal liver stage in definitive erythroid cells in
humans, whereas transgenic -globin is expressed in the primitive stage in yolk sac
erythroid cells in mice. This difference in regulation may reflect a difference in the
availability or function of various trans-acting factors in the mouse compared to humans.
In order to delineate the role of KLF1 in human fetal globin gene regulation we
used erythroid cells derived from human umbilical cord blood CD34+ hematopoietic
progenitor cells, as a model more representative of the fetal milieu than analogous
91

models derived from adult peripheral blood CD34+ cells. In these cells, - and -globin
are expressed at similar levels on day 8 of erythroid differentiation (Fig 4.1A), confirming
that these in vitro cultured cells are similar to the erythroid cells of a new-born in their
hemoglobin phenotype, and -globin expression is not yet silenced as it is in adult
erythroid cells (Alhashem 2012, Weatherall 2001). The pattern of KLF1 and KLF2
expression in these cells is similar to the pattern observed in mouse fetal liver definitive
erythroid cells, with ten-fold higher expression of KLF1 compared to KLF2 (Fig. 4.1B)
(Alhashem 2012, Alhashem et al. 2011). Both KLF1 and KLF2 bind to the -globin
promoter in these cells. However, there is greater enrichment of KLF1 binding to the globin promoter than to the -globin promoter (Fig. 4.2A). Furthermore, KLF2 displays
an impressive enrichment at the -globin promoter, whereas it does not bind to the globin promoter (Fig. 4.2B) (Alhashem 2012).
These initial studies suggest that KLF1 may have a more influential role in globin gene regulation, and KLF2 may be important for -globin gene regulation. Based
on these results, we wished to determine first whether the role of KLF1 in regulating the
expression of -globin in fetal erythroid cells is similar to or divergent from its role in
adult erythrocytes. Our second aim was to investigate whether KLF2 participates in the
regulation of globin gene expression in definitive erythroid cells, particularly with respect
to control of -globin expression. Since KLF2-/- mice die early in development around
the time of onset of definitive erythropoiesis, it is difficult to study its role in definitive
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Figure 4.1: Expression patterns of (A) - and -globin and (B) KLF1 and KLF2 in
erythroid cells derived from cord blood hematopoietic precursors.
Adapted from Alhashem 2012.
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Figure 4.2: Binding of (A)KLF1 and (B) KLF2 to various sites in the -globin locus
in erythroid cells derived from cord blood hematopoietic precursors.
Adapted from Alhashem 2012.
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erythroid cells in the mouse. Our previous research has revealed that KLF1 and KLF2
have overlapping roles in globin gene regulation in the mouse. It was therefore of
interest to determine whether KLF1 and KLF2 have similar functions in human globin
gene regulation.
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4.2 RESULTS
*Sections 4.2.1 to 4.2.4 of the following work were done in collaboration with Dr. Yousef
Alhashem.

4.2.1 KLF1 is a positive regulator of -globin expression in erythroid cells derived
from human umbilical cord blood CD34+ hematopoietic progenitors
In order to determine whether KLF1 positively regulates -globin expression in
human fetal erythroid cells, CD34+ hematopoietic progenitor cells were isolated from
umbilical cord blood samples infected with lentiviral particles carrying KLF1-targeted
shRNA-coding sequences, and differentiated along the erythroid lineage as described in
Methods section 2.2. This system is considered to be more representative of a fetal
erythroid milieu in comparison to a parallel system that uses CD34+ hematopoietic
progenitors isolated from adult mobilized peripheral blood. On day 8 of differentiation
(DD8), erythroid cells were harvested and processed for RNA extraction to analyze
gene expression. Two different shRNAs, K1V1 and K1V2, that target different seed
sequences in the KLF1 mRNA, were used to knock down KLF1 by RNA interference.
K1V1 produced a knockdown efficiency of approximately 50% (Yousef Alhashem, Fig
4.3). K1V2 produced a more efficient knockdown, ranging between 50% and 90%
knockdown efficiency (Fig 4.3).
Because KLF1 is known to regulate numerous aspects of erythroid cell
differentiation, it is important to confirm that modulation of KLF1 levels does not
adversely affect maturation of erythroid cells and to ensure that test and control
samples being compared are composed of similarly staged erythroid cells
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Figure 4.3: KLF1 knockdown efficiency. KLF1 mRNA amount was measured by qRTPCR and normalized to Cyclophilin A mRNA as the internal standard for qRT-PCR. The
amount of KLF1 in scramble-treated cells after normalization to Cyclophilin A was set to
100 for each individual/sample. n = 3 for K1V1 shRNA and n = 11 for K1V2 shRNA.
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Figure 4.4: KLF1 knockdown does not adversely affect erythroid differentiation on
differentiation day 8 (DD8). Representative flow cytometry plots for scramble shRNAinfected and K1V2 shRNA-infected cells showing that the majority of erythroid cells are
double positive for CD71 and CD235a in both scramble-treated and K1V2 shRNAinfected cells on day 8 of differentiation. n=3 for each treatment level.
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(Siatecka and Bieker 2011). In order to assess the stage of erythroid differentiation,
cells were stained with APC-conjugated anti-CD71 (transferrin receptor) antibody and
PE-conjugated anti-CD235a (Glycophorin A) antibody, as described in Chapter 2
(Section 2.2.5). The majority of cells infected with the control scramble shRNA (SCR)
fall in the CD71+CD235a+ or double positive quadrant (79%  27.6, n = 3). Cells infected
with the KLF1-targeted shRNA K1V2 also populate the CD71+CD235a+ quadrant (78%
 21.7, n = 3), indicating that KLF1 knockdown does not affect erythroid maturation at
day 8 of in vitro differentiation (DD8). Additionally, the stage of differentiation of
scramble shRNA-infected cells was compared to the stage of differentiation of “mock”
infected cells (cells that are not infected with a virus but which are cultured in the same
manner as virus-infected cells) to ensure that viral infection does not compromise
erythroid differentiation. The stage of differentiation of scramble shRNA-infected cells
(79%  27.6 CD71+CD235a+, n = 3) is similar to that of mock-treated cells (70%  24.4
CD71+CD235a+, n = 3), confirming that viral infection does not alter erythroid
differentiation in these cells. Representative flow cytometry plots for scramble shRNAinfected and K1V2 shRNA-infected cells are shown in Figure 4.4.
KLF1 knockdown resulted in decreased expression of -globin mRNA compared
to scramble shRNA controls, resembling observations in adult erythroid cells (Fig 4.5).
The reduction in the amount of -globin mRNA correlates positively and significantly
with the residual amount of KLF1 mRNA in the cells (r2 = 0.64, Prob>F = 0.0006, Fig
4.5). Thus the role of KLF1 in regulation of -globin expression is similar in erythroid
cells derived from CD34+ hematopoietic progenitors of both umbilical cord blood as well
mobilized adult peripheral blood (Zhou et al. 2010).
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Figure 4.5: KLF1 is a positive regulator of -globin expression in erythroid cells
derived from human umbilical cord blood CD34+ hematopoietic progenitors. The
amount of KLF1 mRNA and -globin mRNA was measured by qRT-PCR and
normalized to Cyclophilin A mRNA. The fold change in KLF1 expression and -globin
expression in each sample was calculated by setting the value for each gene in
scramble controls to 100. A correlation was observed between the amount of KLF1
mRNA present in cells and the corresponding amount of -globin expression by linear
regression analysis. n = 14, r2 = 0.64, Prob>F = 0.0006. Each dot on the correlation plot
represents a biological sample, i.e. cells obtained from one umbilical cord. Samples that
were infected with the K1V1 shRNA are represented as blue dots and samples that
were infected with the K1V2 shRNA are represented as red dots.
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Figure 4.6: Regulation of -globin expression by KLF1 in erythroid cells derived
from human umbilical cord blood CD34+ hematopoietic progenitors follows a
non-linear pattern. The amount of KLF1 mRNA and -globin mRNA was measured by
qRT-PCR and normalized to Cyclophilin A mRNA. The fold change in KLF1 expression
and -globin expression in each sample was calculated by setting the value for each
gene in scramble controls to 100. No correlation was observed between the amount of
KLF1 mRNA present in cells and the corresponding amount of -globin expression by
linear regression analysis. When the data was analyzed by allowing the statistical
program JMP to fit a non-linear model to the available data in an unbiased manner, the
smooth curve shown in the figure was obtained. The non-linear model supports our
interpretation of the data with regard to sensitivity of the regulation of -globin gene
expression to the amount of KLF1 available in cells. n = 14. Each dot on the scatter-plot
represents a biological sample, i.e., cells obtained from one umbilical cord. Samples
that were infected with the K1V1 shRNA are represented as blue dots and samples that
were infected with the K1V2 shRNA are represented as red dots.
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4.2.2 Regulation of -globin expression by KLF1 in erythroid cells derived from
human umbilical cord blood CD34+ hematopoietic progenitors follows a nonlinear pattern
We next analyzed expression of -globin after knockdown of KLF1. We observed
that with partial KLF1 knockdown, when there is between 20-60% residual KLF1 in
cells, there is a 1.5 to 2-fold increase in -globin expression compared to scrambled
shRNA controls (Fig 4.6). This result concurs with previous observations in KLF1depleted adult erythroid cells as well as in people with heterozygous mutations in the
KLF1 gene with respect to the negative regulation of -globin expression by KLF1 (Borg
et al. 2010; Zhou et al. 2010). However, with robust knockdown, when there is less than
10% residual KLF1 in cells, an approximately 40% reduction in -globin expression is
observed (Fig 4.6). This result is in agreement with data obtained from KLF1 knockout
mouse studies (Alhashem et al. 2011). Thus the relationship between the amount of
KLF1mRNA present in cells and the corresponding amount of -globin expression
appears to be non-linear in nature and not as straight-forward as previously believed.
4.2.3 KLF1 positively regulates Bcl11a expression
Studies in adult human erythroid cells have shown that Bcl11a is a repressor of globin expression (Sankaran et al. 2008), and that Bcl11a is positively regulated by
KLF1 (Borg et al. 2010; Zhou et al. 2010). We studied the expression of Bcl11a in
umbilical cord blood derived erythroid cells to determine whether changes in Bcl11a
expression may be an intermediate determining factor in the observed non-linear
pattern of -globin regulation by KLF1. Bcl11a mRNA is decreased in KLF1 knockdown
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Figure 4.7: KLF1 positively regulates Bcl11a expression. The amount of KLF1
mRNA and Bcl11a mRNA was measured by qRT-PCR and normalized to Cyclophililn A
mRNA. The fold change in KLF1 expression and Bcl11a expression in each sample was
calculated by setting the value for each gene in scramble controls to 100. A correlation
was observed between the amount of KLF1 mRNA present in cells and the
corresponding amount of Bcl11a expression by linear regression analysis. n = 14, r2 =
0.67, Prob>F = 0.0012. Each dot on the correlation plot represents a biological sample,
i.e. cells obtained from one umbilical cord. Samples that were infected with the K1V1
shRNA are represented as blue dots and samples that were infected with the K1V2
shRNA are represented as red dots.
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Figure 4.8: KLF2 expression is upregulated in KLF1 knockdown erythroid cells.
The amount of KLF2 mRNA was measured by qRT-PCR in scramble-treated and K1V2
shRNA-treated cells and normalized to Cyclophililn A mRNA. The fold change in KLF2
expression in each sample was calculated by setting the value for the amount of KLF2
mRNA in scramble controls to 100. n = 4, * = p<0.05.
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cells compared to scramble controls, and the reduction in Bcl11a mRNA amounts
positively correlates with the reduction in KLF1 mRNA in the respective sample (r2 =
0.67, Prob>F = 0.0012, Fig 4.7). The pattern of Bcl11a expression obtained with KLF1
knockdown is more similar to the pattern of -globin expression than to the pattern of globin expression observed with KLF1 knockdown in erythroid cells derived from cord
blood hematopoietic progenitors, suggesting that regulation of -globin expression by
Bcl11a may not be a direct effect.
4.2.4 KLF2 expression is upregulated in KLF1 knockdown erythroid cells
Gene expression analyses in KLF1-/- mouse embryonic erythroid cells revealed
that KLF2 mRNA expression is upregulated in the absence of KLF1. Since KLF1 and
KLF2 have overlapping functions in erythroid gene regulation, this increase in KLF2
expression is suggestive of a compensatory mechanism. In order to determine whether
a similar upregulation of KLF2 is observed when KLF1 mRNA amounts are diminished
in human erythroid cells, we determined the amount of KLF2 mRNA in KLF1 knockdown
cells compared to scramble control cells. KLF2 mRNA amount is approximately 4-fold
elevated in KLF1 knockdown (K1V2) human erythroid cells compared to scramble
(SCR) control cells (p-value = 0.023, n = 4), similar to observations in KLF1-/- mouse
embryonic erythroid cells (Fig 4.8). This increase, although significant, is extremely
variable between samples as is evident from the large standard deviation, perhaps
indicating that KLF1 does not directly regulate KLF2 (Fig 4.8).
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4.2.5 KLF2 positively regulates - and -globin expression in erythroid cells
derived from human umbilical cord blood CD34+ hematopoietic progenitors
We hypothesized that KLF2 may positively regulate -globin expression and that
an increased amount of KLF2 in KLF1 knockdown erythroid cells may be a critical factor
in activating -globin expression in these cells. To determine whether KLF2 regulates globin expression in human erythroid cells derived from cord blood CD34+
hematopoietic progenitors, we knocked down KLF2 mRNA in these cells by RNA
interference. Two different shRNAs, K2sh_206 and K2sh_1529 that target different
seed sequences in the KLF2 mRNA were used. The transduction efficiency was >70%
with both KLF2-targeting shRNAs as well as with a control, scramble (SCR) shRNA
(n=3 for each shRNA). K2sh_206 produced a knockdown efficiency of approximately
65% and K2sh_1529 produced a knockdown efficiency of approximately 50% (Fig 4.9).
In order to assess the stage of erythroid differentiation, cells were stained with
APC-conjugated anti-CD71 (transferrin receptor) antibody and PE-conjugated antiCD235a (Glycophorin A) antibody, as described above. The majority of cells infected
with the control scramble shRNA (SCR) fall in the CD71 +CD235a+ or double positive
quadrant (80.50.35%, n = 2). Cells infected with both KLF2-targeted shRNAs,
K2sh_206 (79.62.12%, n = 2) and K2sh_1529 (83.51.63%, n = 2), also populate the
CD71+CD235a+ quadrant, indicating that KLF2 knockdown does not affect erythroid
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Figure 4.9: KLF2 knockdown efficiency in erythroid cells derived from cord blood
precursors. KLF2 mRNA amount was measured by qRT-PCR and normalized to
Cyclophilin A mRNA as the internal standard for qRT-PCR. The amount of KLF2 in
scramble-treated cells (SCR) after normalization to Cyclophilin A was set to 100 for
each sample. n = 3 for each treatment level.

106

MOCK DD8

SCR_shRNA DD8

77.14.7

80.50.35

CD71-APC

K2_sh206 DD8

K2_sh1529 DD8

79.62.1

83.51.6

GPA-PE-Cy7
Figure 4.10: KLF2 knockdown does not adversely affect erythroid differentiation
on differentiation day 8 (DD8). Representative flow cytometry plots for mock,
scramble shRNA-infected, K2_sh206 shRNA-infected and K2_sh1529 shRNA-infected
cells showing that the majority of erythroid cells are double positive for CD71 and
CD235a in mock cells, scramble-treated cells and in both KLF2 shRNA-infected groups
on day 8 of differentiation. n=3 for each treatment level.
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maturation at day 8 of in vitro differentiation (DD8). Additionally, the stage of
differentiation of scramble shRNA-infected cells is compared to the stage of
differentiation of mock infected cells to ensure that viral infection does not compromise
erythroid differentiation. The stage of differentiation of scramble shRNA-infected cells
(80.50.35% CD71+CD235a+, n = 2) is similar to that of mock-treated cells (77.14.7%
CD71+CD235a+, n = 2), confirming that viral infection does not alter erythroid
differentiation in these cells. Representative flow cytometry plots for mock-treated,
scramble shRNA-infected, K2sh_206 and K2sh_1529 shRNA-infected cells are shown
in Figure 4.10.
KLF2 knockdown resulted in decreased expression of -globin mRNA compared
to scramble shRNA controls, with both the KLF2-targeting shRNAs, K2sh_206 and
K2sh_1529 (Fig 4.11). There was an approximately 25% reduction in the amount of globin mRNA in erythroid cells infected with K2sh_206 compared to scramble-infected
cells. Infection with the second KLF2 shRNA construct, K2sh_1529, resulted in an
approximately 40% decrease in the amount of -globin mRNA compared to scrambleinfected cells. Surprisingly, knocking down KLF2 also resulted in a decrease in the
amount of -globin mRNA in these cells compared to scramble controls (Fig 4.12).
Knockdown of KLF2 with both K2sh_206 and K2sh_1529 resulted in approximately 40%
less -globin mRNA compared to scramble shRNA-treated cells.
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Figure 4.11: KLF2 positively regulates -globin expression in erythroid cells
derived from human umbilical cord blood CD34+ hematopoietic progenitors. The
amount of -globin mRNA was measured by qRT-PCR in scramble-treated and KLF2
shRNA-treated cells and normalized to Cyclophililn A mRNA. The fold change in globin expression in each sample was calculated by setting the value for the amount of
-globin mRNA in scramble controls to 100. n = 3 for each treatment level, * = p<0.05.
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Figure 4.12: KLF2 positively regulates -globin expression in erythroid cells
derived from human umbilical cord blood CD34+ hematopoietic progenitors. The
amount of -globin mRNA was measured by qRT-PCR in scramble-treated and KLF2
shRNA-treated cells and normalized to Cyclophililn A mRNA. The fold change in globin expression in each sample was calculated by setting the value for the amount of
-globin mRNA in scramble controls to 100. n = 3 for each treatment level, * = p<0.05.
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4.3 DISCUSSION
The recent development of a human in vitro primary cell culture system has
enabled researchers to study mechanisms that control regulation of the human -globin
genes, particularly regulation of the -globin gene, in their natural environment, i.e. in
human erythroid cells, as opposed to studying their regulation in foreign cells such as
mouse cells or compromised cells such as erythroleukemia cells (Migliaccio et al. 2002).
Using this model, erythroid cells are obtained for study by isolation of CD34+
hematopoietic progenitor cells from mobilized adult peripheral blood, umbilical cord
blood, or bone marrow, followed by expansion and differentiation along the erythroid
lineage. A further advantage of this model is the ability to manipulate the expression of
various genes of interest by RNA interference and study downstream effects. The focus
of our research is to understand the role of Krüppel-like transcription factors, KLF1 and
KLF2, in regulation of the -globin gene. We are particularly interested in mechanisms
that control activation of -globin expression. As -globin is normally expressed in fetal
liver erythroid cells in humans, we isolated CD34+ hematopoietic progenitors from
umbilical cord blood and differentiated them into erythroid cells, representing a more
“fetal” than “adult” model system for the study of globin gene regulation (Alhashem
2012). We have employed this model to study the effect of depletion of either KLF1 or
KLF2 mRNA on regulation of the -like globin genes. This led to the identification of
novel roles for both KLF1 and KLF2 in regulating human -like globin gene expression.
Studies using erythroid cells derived from adult hematopoietic progenitors had
previously demonstrated that depletion of KLF1 results in derepression of the -globin
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gene in these cells (Borg et al. 2010; Zhou et al. 2010). We have shown here that globin expression is sensitive to KLF1 dosage. When KLF1 is depleted in the fetal
model such that there is between 20% and 60% remaining KLF1 in cells, -globin
expression elevated approximately 1.5- to 2.5-fold higher than expression in control
cells. The degree of up-regulation in -globin expression varies greatly from sample to
sample, or in other words, between people. For example, out of two samples with 5560% remaining KLF1, one showed a 2-fold increase in -globin expression whereas the
other showed a 1.3-fold increase. Similarly, out of four samples that had 15-20%
remaining KLF1, two showed a 1.4-fold and 1.6-fold increase in -globin expression
while the other two showed no change in -globin expression compared to control. This
variation in the -globin up-regulation is also observed in people with heterozygous
mutations in KLF1. Ten individuals from a Maltese family who have the same KLF1
mutation varied in HbF levels between 3% and 19.5% (Borg et al. 2010). Fluctuations in
-globin up-regulation are probably the result of differences between people at certain
loci that behave as genetic modifiers. For example, heterozygosity at SNP rs766432 in
the Bcl11a locus may contribute to some of the observed variation in the Maltese HPFH
pedigree (Borg et al. 2010). Additionally, the increase in -globin expression observed in
our experiments with cells of cord blood origin, with KLF1 knockdown, is less
pronounced than the corresponding 6- to 10-fold increase seen in adult erythroid cells in
which KLF1 levels are depleted (Borg et al. 2010; Zhou et al. 2010). These differences
may reflect inherent limitations in the capacity of gene activation, since -globin is
already actively expressed in erythroid cells of the fetal model whereas it is almost
completely silenced in the adult model.
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We have shown here for the first time that depletion of KLF1 mRNA amount to
less than 10% of normal levels results in decreased expression of the -globin gene.
This finding corroborates observations in KLF1-/- -YAC mice in which KLF1 ablation
led to decreased -globin expression in mouse embryos (Alhashem et al. 2011).
Interestingly, in both KLF1 knockdown human erythroid cells as well as KLF1-/- -YAC
mice, lack of KLF1 reduced -globin expression only by 50%, whereas -globin
expression is more severely affected, indicating that regulation of the -globin gene is
more dependent on KLF1 than regulation of the -globin gene. We hypothesize that
elevated -globin expression in cells with partial KLF1 depletion is caused by
dysregulation of modifiers of -globin expression, such as Bcl11a and KLF2, that are
intermediate between KLF1 and -globin in the natural order of regulatory events and
that may or may not be directly regulated by KLF1. Elevation in -globin expression may
also result from reduced ability of the -globin promoter to compete for the LCR due to a
reduction in KLF1 binding to its promoter. We hypothesize that decreased - and globin expression in cells with almost complete KLF1 depletion may result from loss of
LCR interactions with both the - and -globin gene promoters due to diminished active
chromatin hub formation at the -locus and diminished recruitment of the - and -globin
genes to transcription factories, all of which require KLF1 (Drissen et al. 2004;
Schoenfelder et al. 2010).
We demonstrate in this study that KLF2 plays a positive role in -globin gene
regulation in human erythroid cells. Earlier evidence from -YAC mice indicated that
deletion of the KLF2 gene causes decreased -globin expression during primitive
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erythropoiesis in mouse embryos (Alhashem et al. 2011). It has not been possible to
study the effect of KLF2 ablation on definitive erythropoiesis in mice due to early
embryonic lethality (Kuo et al. 1997; Wani, Means, Lingrel 1998). Partial depletion of
KLF2 in our in vitro human fetal erythroid cell model resulted in a modest decrease in globin expression. KLF2 binds robustly to the -globin promoter in these cells
(Alhashem 2012). It will be interesting to determine whether the amount of the decrease
in -globin expression correlates with the amount of the decrease of KLF2 in these cells.
KLF2 depletion also resulted in reduced -globin expression. This observation came as
a surprise because KLF2 neither regulates the mouse maj-globin gene, nor does it bind
to the adult -globin promoter in either mouse or cord blood derived human erythroid
precursor cells. A decrease in the amount of both - and -globin expression in erythroid
cells is often indicative of an inhibition of erythroid differentiation. We have assessed the
levels of CD71 and CD235a by flow cytometry and found that the distribution of these
erythroid cell surface markers is not altered in KLF2 knockdown cells compared to
control cells. It is possible that marginal defects in the differentiation of erythroid cells
may not be detected by this method because each gate of the flow cytometry analysis
corresponds to more than one population of erythroid precursor cells (see section 1.1.3)
(Pilon, Mol Cell Biol 2008). To address this possibility the relative number of
proerythroblasts,

basophilic

erythroblasts,

polychromatophilic

erythroblasts

and

orthochromatic erythroblasts will be determined in KLF2 knockdown samples compared
to scramble-treated controls using Giemsa-stained cytospins (Alhashem 2012). The
expression of -globin will also be compared in KLF2 knockdown and control samples.
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If differentiation is unperturbed, the amount of -globin expression should not vary
between KLF2 knockdown and control samples.
An alternative explanation for reduced - and -globin expression in KLF2
knockdown erythroid cells is that KLF2 may be required for normal chromatin structure
at the -locus. Although there is no prior evidence that KLF2 has a role in -locus
organization, it is possible that KLF2 may have a function similar to KLF1 in this respect.
Changes in locus organization in the absence of KLF2 would explain the observed
reduction in -globin gene expression despite the fact that KLF2 does not bind to the globin promoter. 3C assays can be used to determine whether KLF2 is required for
interactions between the LCR and the globin gene promoters. Another possibility is that
KLF2 may regulate gene expression through interactions with histone acetyl
transferases, p300/CBP and PCAF. There is evidence that the KLF1 and KLF2 proteins
physically interact with p300/CBP and PCAF in cells (Das et al. 2006; SenBanerjee et
al. 2004; Zhang and Bieker 1998). A reduction in activating histone marks, H3K4Me3
and H3K9Ac, and a reduction in RNA Polymerase II (RNAPol II) recruitment was
observed at the -globin promoter in KLF1 knockdown erythroid cells compared to
control cells derived from cord blood precursors (Alhashem 2012). H3K4 trimethylation,
H3K9 acetylation and RNAPol II recruitment will be assessed in KLF2 knockdown
erythroid cells compared to controls to determine whether KLF2 affects activating
histone marks across the -locus. A third possibility is that KLF2 may indirectly regulate
the -globin gene by controlling the expression of other factors required for optimal globin expression. KLF1 expression was slightly reduced in KLF2-/- mouse embryonic
yolk sacs (Basu P, unpublished data). The expression of KLF1 will be quantitated in
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KLF2 knockdown human erythroid cells to determine whether KLF2 positively regulates
KLF1 expression. If KLF2 positively regulates KLF1 expression, that would directly
affect -globin expression. Thus this study begins to address the role of KLF1 and KLF2
in human erythroid cells with a “fetal” pattern of -like globin gene expression and offers
many exciting avenues for further exploration. Figure 4.13 is a schematic that
consolidates our current data obtained using the cord-blood derived erythroid cells with
the existing model for globin gene regulation, centered on KLF1 and KLF2.
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Figure 4.13: A schematic outlining -like globin gene regulation by KLF1 and
KLF2. KLF2 positively regulates KLF1 in mouse embryonic yolk sac cells. The question
mark between KLF1 and KLF2 in the figure indicates that it is yet to be determined
whether KLF2 regulates KLF1 expression in human erythroid cells.
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Chapter 5: Discussion and Future Directions
The mouse has proved an invaluable system for the study of biological
processes especially with regard to identifying gene function using gene knockout
models. Striking advantages of the mouse as a model organism include the high degree
of similarity between mouse and human genomes (>99%) and physiology, short
gestation period and breeding cycle, large litter size, ease of genetic manipulation and
relatively smaller space requirements than other mammals (Peters et al. 2007;
Rosenthal and Brown 2007). Advances in our understanding of the control of globin
gene regulation and the molecular pathophysiology of hemoglobinopathies have
depended upon access to a plethora of mouse genetic tools (Bauer, Kamran, Orkin
2012; Tsiftsoglou, Vizirianakis, Strouboulis 2009). In particular, the mouse is a great
system to study developmental processes like primitive erythropoiesis that are not as
easy to study in humans due to ethical concerns and a lack of accessibility to relevant
tissues during early embryonic development.
Like humans, mice show two waves of erythropoiesis, primitive erythropoiesis
that originates in the yolk sac and definitive erythropoiesis that occurs at multiple sites
within the embryo proper. The human -globin locus consists of five -like globin genes:
ε, G, A,  and  globin. Similar to humans, the mouse -globin locus consists of four
temporally and spatially regulated -like globin genes: Ey, h1, maj and min. Both the
human and mouse -globin genes are dependent on the presence of an upstream locus
control region (LCR) for robust expression. Studies using gene-targeting strategies in
mice to abolish the expression of specific genes have led to the elucidation of a network
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of transcription factors that are important for erythropoiesis (Fig. 5.1) (Loose and Patient
2006; Swiers, Patient, Loose 2006). An added layer of specificity has been provided by
the development of conditional knockout mice which allow cell-type-specific ablation of
genes (Mikkola and Orkin 2005). Conditional knockout mice have been instrumental in
dissecting cell-autonomous and non-cell-autonomous roles of factors that are
expressed in multiple cell types. The primary advantage of a mouse model is that the
effect of gene ablation can be studied in vivo, in the context of the entire organism
replete with various intercellular and systemic interactions, as opposed to ex vivo cell
culture systems in which cells are grown in relative isolation.
In this study we have used knockout models that ablate the expression of KLF1
and KLF2 in mice to study the overlapping roles of these related transcription factors in
primitive erythropoiesis. We have also used a conditional knockout model to determine
the erythroid cell-autonomous role of KLF2, which is expressed in lymphocytes and
endothelial cells in addition to erythroid cells. Previous studies have shown that
simultaneous ablation of KLF1 and KLF2 results in early embryonic lethality and severe
anemia in mouse embryos (Basu et al. 2007). In this study, we show that this anemia is
caused by a paucity of blood cells, and exacerbated by diminished -like globin gene
expression. The anemia phenotype is dose-dependent, and interestingly, can be
ameliorated by a single copy of the KLF2, but not the KLF1 gene. The roles of KLF1
and KLF2 in maintaining both normal peripheral blood cell numbers and globin mRNA
amounts are erythroid cell-specific. It was discovered that KLF2 has an essential
function in erythroid precursor maintenance. KLF1 can partially compensate for KLF2 in
this role, but is uniquely crucial for erythroid precursor proliferation, through its
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Figure 5.1: A model genetic network that regulates erythroid development based
on the results of gene-targeting studies in mice. Adapted from (Loose and Patient
2006; Swiers, Patient, Loose 2006)
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regulation of G1- to S-phase cell cycle transition. A more drastic impairment of primitive
erythroid colony formation from embryonic progenitor cells occurs with simultaneous
loss of KLF1 and KLF2, than with loss of a single factor. The results of this study have
been instrumental in designing experiments to explore the roles of KLF1 and KLF2 in
human fetal and adult erythropoiesis. These discoveries are also pertinent to the
development of therapeutic strategies to elevate -globin expression in adult erythroid
cells. It is important that the results of this study and others similar to it, that delineate
the basic biological processes controlled by various transcription factors, inform
attempts to modulate the levels of these factors (including KLF1 and BCL11a) to elevate
-globin expression.
The study of the overlapping roles of KLF1 and KLF2 in mouse embryonic
erythropoiesis has provided us with clues regarding how these factors interact to
regulate downstream gene expression and what processes they may co-regulate in
mouse and human erythroid cells. However, it is not known how the gene interactions
between KLF1 and KLF2 are functionally played out in cells. There is no evidence for
dimerization of these factors. KLF1 and KLF2 bind to DNA via recognition of a CACCC
sequence, which is the common binding motif for both factors, as well as for other KLFs.
While some gene promoters have multiple CACCC binding sites, others have only one
CACCC site. Additionally, enrichment of both KLF1 and KLF2 is often observed at the
same CACCC site. This observation indicates that in a population of cells, KLF1 is
bound to a certain CACCC site in a portion of alleles, whereas KLF2 is bound to the
same site in a portion of alleles. Thus if both KLF1 and KLF2 have equal affinity to a
particular CACCC binding site and compete for binding at that site, the respective level
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of each protein in a cell may have functional significance to the cell’s transcriptional
output. Furthermore, if either factor is evaluated as a potential therapeutic target or is
downstream of a potential therapeutic target, the function of the other may also be
dysregulated in this paradigm. In an endeavor to further characterize the functional
overlap between KLF1 and KLF2, studies from our laboratory identified the subset of
genes that are synergistically down-regulated in KLF1-/-KLF2-/- embryonic erythroid
cells compared to KLF1-/- and wild-type erythroid cells using microarray technology
(Pang et al. 2012). These studies identified c-myc as a central factor in the network of
genes co-regulated by KLF1 and KLF2. They also identified groups of genes belonging
to certain functional categories including cellular proliferation, apoptosis and
homeostasis, as significantly down-regulated in KLF1-/-KLF2-/- erythroid cells. For
future experiments, it will be interesting to determine the genome-wide binding profile of
KLF2 in erythroid cells by ChIP-seq and compare the binding profiles of KLF1 and KLF2
to each other and to the expression profiling results from KLF1/KLF2 double knockouts.
To further our understanding of the functional redundancy of KLF1 and KLF2, it will be
intriguing to determine whether expression of the KLF2 gene in a pattern similar to the
KLF1 gene in erythroid cells can rescue lethality of KLF1-/- embryos by generating a
transgenic mouse model in which the KLF2 gene is expressed under the control of the
KLF1 promoter. Gene interactions amongst related members of transcription factor
families that are functionally relevant to hematopoiesis have been discovered for
multiple groups of genes including the GATA family members, Gata1 and Gata2
(Fujiwara et al. 2004), the Runx family members Runx1, Runx2 and Runx3 (Wang et al.
2010), and more recently for the Snail family members Snai2 and Snai3 (Pioli and Weis
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2014). However, the mechanisms governing these interactions are not well understood.
Observations from the study of bHLH transcription factors Hand1 and Hand 2 belonging
to the Twist gene family, that display gene interactions and functional redundancy in
cardiovascular development, have highlighted the importance of level of expression
(gene dosage) of interacting genes and the effect of post-translational modifications on
the outcome of gene interactions (Conway, Firulli, Firulli 2010).It is known that KLF1
function is regulated by various post-translational modifications including acetylation,
phosphorylation and sumoylation (Siatecka and Bieker 2011). KLF2 is known to interact
with E3 ubiquitin ligase WWP1, which suppresses its transactivation potential
(Conkright, Wani, Lingrel 2001). It will be of interest to determine how these posttranslational modifications affect KLF1 and KLF2 gene interactions by generating mice
with point mutations of the relevant residues.
The major difference between humans and mice with respect to the -globin
locus is that in humans ε-globin is expressed in yolk sac primitive erythroid cells and globin is expressed predominantly in fetal liver erythroid cells, whereas in mice both Ey
and h1 are expressed in embryonic erythroid cells and there is no fetal gene
equivalent to the human -globin gene. In an effort to directly study regulation of the
human -globin locus, transgenic mice were generated that carry the entire human globin locus in addition to the endogenous mouse globin genes (Gaensler, Kitamura,
Kan 1993; Peterson et al. 1993). These mice are popularly referred to as the -YAC
mice. Although the human -like globin genes are expressed in a tissue- and
developmental stage-specific manner in the -YAC mice, -globin is expressed in yolk
sac erythroid cells coincident with ε-globin and the endogenous mouse embryonic
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globin genes and not in mouse fetal liver erythroid cells. This discrepancy in -globin
expression is the main drawback of the -YAC model, which has otherwise been
instrumental in deciphering developmental control of globin gene regulation including
elucidation of interactions between the LCR and the promoters of the globin genes.
Research in the last two decades has unveiled multifaceted roles for KLF1 in the
control of globin gene regulation (reviewed in(Tallack and Perkins 2013). KLF1 directly
regulates the expression of the -globin gene by binding to its promoter at a CACCC
site. KLF1 is required for physical interactions between the LCR and the -globin
promoter, as well as for the formation of an active chromatin hub at the -locus (Drissen
et al. 2004). In addition to its “local” functions at the -globin locus, KLF1 also has more
global regulatory portfolio. Intra- and inter-chromosomal associations between the globin gene and other KLF1-regulated genes, as well as recruitment of these genes to
transcription factories were shown to be KLF1-dependent in erythroid cells
(Schoenfelder et al. 2010).
There is dichotomy in the literature with respect to the role of KLF1 in -globin
gene regulation. Evidence from studies in adult erythroid cells suggested that KLF1
negatively regulates the expression of the -globin gene (Borg et al. 2010; Zhou et al.
2010). These observations gained credence from the fact that certain people with
heterozygous mutations in the KLF1 gene show elevated levels of -globin and HbF
(Arnaud et al. 2010; Borg et al. 2010). However, studies using compound KLF1-/- / YAC transgenic mice had divergent results. At the embryonic stage, when -globin is
actively expressed in these mice, KLF1 ablation caused a decrease in -globin
expression (Alhashem et al. 2011). Furthermore, KLF1 was detected bound to the 123

globin promoter in primitive erythroid cells from wild-type -YAC transgenic mice. At the
fetal liver stage, when -globin is silenced in the -YAC mice, elevated -globin mRNA
expression was observed in KLF1+/- and KLF1-/- fetal livers (Perkins, Gaensler, Orkin
1996; Wijgerde et al. 1996). However, in adult KLF1+/- mice expression of the -globin
gene was silenced (Wijgerde et al. 1996). Results from our investigations into the role of
KLF1 in erythroid cells derived from cord blood hematopoietic progenitors indicate that
both increased -globin expression and decreased -globin expression can result from
down-regulation of KLF1. Expression of the -globin gene appears to be sensitive to
small changes in the amount of KLF1. Partial depletion of KLF1 (corresponding to
haploinsufficiency) causes elevated -globin expression, while nearly complete
depletion of KLF1 (similar to ablation) results in a down-regulation of -globin
expression. It will be of interest to determine whether this dual mode of -globin gene
regulation is accompanied by changes in LCR interactions with the -globin promoter,
i.e. is there an increased frequency of interactions between the LCR and the -globin
promoter in cells with elevated -globin expression and is there a decrease in the
frequency of interaction between the LCR and the -globin promoter in cells with
decreased -globin expression compared to control cells. Changes in the frequency of
interaction between the LCR and the -globin promoter can be assessed using
chromosome conformation capture (3C) assays.
Thus depletion of KLF1 in erythroid cells may have the dual advantage of downregulating
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hemoglobinopathies while at the same time upregulating the expression of -globin.
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Being an erythroid-specific transcription factor adds to the attraction of modulating
levels of KLF1 as a therapeutic target for -hemoglobinopathies. However, our current
results, as well as extensive studies in KLF1 knockout mice, would advise caution.
Numerous groups have shown that KLF1 regulates many other aspects of
erythropoiesis in addition to globin gene expression (reviewed in (Siatecka and Bieker
2011). KLF1-/- erythroid cells display morphological abnormalities including cell
membrane and nuclear irregularities (Basu et al. 2007; Drissen et al. 2005), defective
erythroid maturation (Basu et al. 2007; Pilon et al. 2008) and dysregulation of global
gene expression in erythroid cells (Drissen, MCB 2005; Hodge, Blood 2006; Nilson, Exp
Hem 2006; Pilon, MCB 2008; Tallack, Genome Res 2010; Pang, Mol Cell Biol
2012)(Drissen et al. 2005; Hodge et al. 2006; Nilson et al. 2006; Pang et al. 2012; Pilon
et al. 2008; Tallack et al. 2010). Hence therapeutic modulation of KLF1 levels should be
approached with careful consideration to possible repercussions.
Negative regulation of -globin by KLF1 is an indirect effect mediated partially by
the repressor Bcl11a, although other factors are probably involved (Borg et al. 2010; Xu
et al. 2013; Zhou et al. 2010). Evidence suggests that KLF1 directly regulates Bcl11a.
There is much advocacy for the pharmaceutical targeting of Bcl11a to elevate -globin
expression. While KLF1 expression appears to share a linear relationship with Bcl11a
expression, this does not translate to a linear relationship between Bcl11a expression
and -globin expression, suggesting that both KLF1 and Bcl11a are indirect negative
regulators of -globin expression. This premise is supported by the fact that Bcl11a
binds not to the promoter of the -globin gene but to an intergenic region between the and -globin genes and interacts with numerous chromatin remodeling factors,
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suggesting that it may play a role in maintaining locus configuration rather than having a
direct effect on -globin repression (Sankaran et al. 2008). Thus modulation of Bcl11a
levels alone may not prove to be an effective therapeutic strategy. Recent studies have
identified Mi2-, a component of the nucleosome remodeling and histone deacetylase
(NURD) complex, as a potent negative regulator of -globin expression, that may prove
to be an alternative therapeutic target (Amaya et al. 2013; Costa et al. 2012).
KLF2 is phylogenetically closely related to KLF1. Mouse KLF1 and KLF2 proteins
are 83% identical to each other within their zinc finger binding domains, while human
KLF1 and KLF2 are 84% identical to each other within this region. Due to this high
degree of similarity, KLF1 and KLF2 are predicted to bind to the same CACCC
consensus sequences. This observation led to the hypothesis and subsequent
experimental confirmation that KLF1 and KLF2 have overlapping roles in regulating
embryonic -like globin gene expression in the mouse (Basu et al. 2007). Additionally,
KLF2 binds to the -globin promoter in primitive erythroid cells from -YAC transgenic
mice and compound KLF2-/- / -YAC transgenic mice show a modest decrease in globin expression (Alhashem et al. 2011). The development of new in vitro culture
techniques for the production and manipulation of human erythroid cells from mobilized
adult peripheral blood and umbilical cord blood hematopoietic progenitors have enabled
researchers to study the regulation of the human -like globin genes in their natural
cellular environment as opposed to earlier studies that depended on murine trans-acting
factors (Migliaccio et al. 2002). We have used this system to study the effect of KLF2
depletion on the regulation of the - and -globin genes in erythroid cells derived from
cord blood hematopoietic progenitors. KLF2 positively regulates -globin expression in
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these cells, analogous to observations in the -YAC mice. Moreover KLF2 binds
robustly to the -globin promoter in these cells, suggesting that regulation of -globin
expression may be a direct effect (Alhashem 2012). The decrease in -globin
expression was modest, ranging between 30% and 40% depending on which shRNA
was used. KLF2 was knocked down by approximately 50% compared to the scramble
control in these initial samples. Further experiments with more efficient knockdowns
need to be done to determine whether decreases in the amount of -globin expression
correlate with reductions in the amount of KLF2 in cells. In order to obtain better
knockdown efficiency, two shRNAs targeting different seed sequences in the KLF2
mRNA will be used simultaneously. If regulation of -globin by KLF2 is a direct effect,
KLF2 will be one of a very small group of factors, including NF-E4, TR2 and TR4,
known to directly activate -globin expression (Sankaran and Orkin 2013). KLF1 and
KLF2 are expressed at similar levels in mouse primitive erythroid cells, which is the
stage at which -globin is expressed in the transgenic -YAC mice. In -YAC fetal liver
erythroid cells, where -globin expression is silenced and -globin is actively expressed,
KLF1 expression is ten-fold higher than KLF2 expression (Alhashem et al. 2011). It will
be particularly interesting to determine whether KLF2 is expressed at different levels in
human “fetal” erythroid cells derived from cord blood precursors compared to “adult”
erythroid cells derived from mobilized peripheral blood.
The CD34+ hematopoietic precursor derived erythroid cells have provided us
with a new human model system in which we can study KLF1 and KLF2 gene
interactions. KLF1 and KLF2 mRNA will be simultaneously depleted in this system by
RNA interference. Because the KLF1-targeting shRNA plasmid has a GFP reporter
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gene and the KLF2-targeting shRNA plasmid has an RFP reporter gene, it will be
possible to retrieve cells that have been virally transduced with shRNAs targeting both
KLF1 and KLF2 by FACS. The expression of the globin genes as well as other genes
that are co-regulated by KLF1 and KLF2 will be assessed in KLF1/KLF2 double
knockdown cells compared to KLF1 knockdown, KLF2 knockdown and scrambletreated cells. Additionally the stage of erythroid differentiation and definitive erythroid
colony-forming ability of KLF1/KLF2 double knockdown cells will be determined. It will
be of interest to determine whether KLF1 and KLF2 have overlapping functions in
human definitive erythropoiesis, akin to their roles in mouse embryonic erythropoiesis.
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